Filetype Excel XLSX | Posted on 10 Aug 2022 | 3 years ago
Authentication
digital resources
219x Filetype XLSX File size 0.34 MB Source: www.nihr.ac.uk
Sheet 1: Procedures
| 2022-2023: Version 1.3 | ||||||
| Workbook content: | ||||||
| This definition and tariff has been created to assist both Industry and NHS partners to create consistent and meaningful costings for Industry sponsored research within the NHS. | ||||||
| Values within this tariff solely define the relevant labour time required by research staff to initiate, carry out or report on the activity described within the Investigation and Intervention Tariff document. | ||||||
| Please note that all values included below are guidelines and may require adaptaion due to complexity or additional staff involvement. | ||||||
| All entries contain the following: | ||||||
| ● Grantplan or NIHR Coding - Codes from the Industry Grantplan software or NIHR coding (for reference) where Grantplan coding is absent. | ||||||
| ● Activity Description - Brief Description of activity taking place | ||||||
| ● Department - Defined department that covers the activity (this may vary from one NHS organisation to another. | ||||||
| ● Notes - Whether the activity is a single investigation, an intervention with associated investigation or a unit cost activity at setup or during the project. | ||||||
| ● Timings - The defined unitary timings for the activity | ||||||
| Please note that these are NHS baseline timimgs only and do not represent costs provided by commercial or academic units. A degree of consideration will be required in order to cost any of these items in conjunction with external NHS SLAs contract to either of these entities. | ||||||
| The following values have been used to convert the timings in this document into unit costs within the tool: | ||||||
| Role | Cost per Hour | |||||
| Medical | £97 | |||||
| Manager/ Nurse | £40 | |||||
| Admin/ Data | £24 | |||||
| Grantplan or NIHR Coding | Activity Description | Department | Notes | Clinical Time [Consultant] |
Nurse Time [Band 7] |
Admin Time [Band 4] |
| NIHR_PRC_001 | Informed consent | STUDY TEAM | Nurse time refers to the study being discussed with the patient prior to consent and signature which is represented by the Clinical (Doctor) time. Nurse time will include the patients being informed of their rights (informed consent process according to GCP guidelines), preliminary reviews of inclusion/exclusion criteria, concomitant medications and medical (with condition history if applicable) and previous laboratory test results if appropriate (please note that these reviews may/will also be conducted by the doctor at the screening visits). Times allocated are dependent on complexity of study and the patient group (cognitive level) and the following time are provided as initial guidance only: From 30 mins for simple complexity (Observational, Genetic databases), From 45 mins medium complexity (majority of types of studies), From 60 mins complex (e.g. monoclonal studies), From 15 mins ADDITIONAL time if patient population requires (e.g. level of cognitive function). Other considerations which may require additional time includes: Pre-screen checks, pre-screen discussion with patient (nurse and PI or referring consultant), handling patient call query when reviewing information, attendance at Screening visit with further questions, the Caregiver or family members may have queries, which may be more common for patient home visits or inclusion of genetic sample requirements. Re-consenting patients following protocol amendment may be required and could be included as an Additional Itemised Cost line item to enable invoicing as required. | 60 | 60 | 0 |
| NIHR_PRC_002 | Consent for Genetic Sample | STUDY TEAM | Nurse time refers to the implications of genetic sampling being discussed with the patient prior to consent for this procedure as a standalone consent. | 10 | 10 | 0 |
| NIHR_PRC_003 | Medical history | STUDY TEAM | May include other information covering demographics, concomitant illnesses or inclusion/exclusion related questions. For some conditions, further information maybe needed around previous treatments or condition history e.g. Diabetes, oncology, Alzheimer''s Disease which may require more time to be included. This could add from 15 mins Clinical time and from 60 mins nurse time depending on requirements and whether discussion have been part of informed consent process |
30 | 30 | 0 |
| NIHR_PRC_004 | Blood sample - collection only | STUDY TEAM | Blood sample collection only. Chargeable per patient collection (blood draw) not per tube. Covers preparation (e.g. cannulation if used), equipment, collection and paperwork. Cost EXCLUDES processing - if required please select additional line item for blood sample collection processing. May need to consider time adjustments when collection is outside of normal working hours (e.g. access restrictions). Where applicable ensure investigator time is included for sign-off’. May be required for pregnancy test (serum hCG) - amend descriptive text to show inclusion as required. | 0 | 15 | 0 |
| NIHR_PRC_005 | Blood sample - collection processing | STUDY TEAM | Blood sample collection processing only (EXCLUDES collection - this is a separate line item). Times to be adjusted as per processing requirements in the protocol. The separate Specimen dispatch item should be selected if using off-site lab (e.g. central lab). May need to consider time adjustments when collection is outside of normal working hours (e.g. access restrictions). Where applicable ensure investigator time is included for sign-off. May be required for pregnancy test (serum hCG at local or central lab) - amend descriptive text to show inclusion as required. | 0 | 30 | 0 |
| NIHR_PRC_006 | Specimen Dispatch by post/courier | STUDY TEAM | Time for staff to package specimens to confirm to appropriate UN Packing standard, arrangement of courier and associated paperwork. Separate line items enables reflective of batch couriering for patient samples if possible. | 0 | 30 | 0 |
| NIHR_PRC_007 | Vital Signs measurements (Temp, BP, Pulse and respiration) | STUDY TEAM | Covering Temperature, blood pressure, pulse rate and respiration rate | 10 | 10 | 0 |
| NIHR_PRC_008 | Weight & Height (including BMI if required) | STUDY TEAM | Additional time may be required if patient has mobility or disability which requires transfer from wheelchair and back or support requirements during measurement. Time may vary depending on equipment or BMI calculation method required by protocol. | 0 | 5 | 0 |
| NIHR_PRC_009 | Waist and Hip Circumference | STUDY TEAM | Waist and Hip Circumference measurement | 0 | 0 | 5 |
| NIHR_PRC_010 | Blood pressure (only) | STUDY TEAM | Line item for use when measurement is performed independently of the vital signs assessments. Time is dependent on specific instructions | 0 | 10 | 0 |
| NIHR_PRC_011 | Physical examination | STUDY TEAM | Timings assume patient without a condition that would result in requiring additional time e.g.. mobility problems Nurse may need follow up by contacting GP or other consultants for results of previous tests. May require different examinations e.g. eye examinations by fundoscopy (5min clinical time) for diabetic patients which would be helpful to list in procedure description to aid review |
30 | 20 | 0 |
| NIHR_PRC_012 | Urinalysis - Urine collection only (at clinic) | STUDY TEAM | Time allocated covers sample collection only. Processing of sample is included as a separate line item. Time value may need adjustment to include time for support for patient to get on/off the toilet if required. May be required for pregnancy test. | 0 | 5 | 0 |
| NIHR_PRC_013 | Urinalysis - Urine processing (dipstick or sample preparation) | STUDY TEAM | Processing of collected Urine (e.g. volume measurement, acidification, centrifugation, transfer of containers) for lab investigations. Processing time may be adjusted to reflect the processing requirements of the protocol including sending off a culture and sensitivity to local labs and following up results. Associated investigation cost may also be required. May be required for pregnancy test. | 0 | 5 | 0 |
| NIHR_PRC_014 | Spirometry | STUDY TEAM | Includes preparation, use and cleaning of spirometer equipment and standard consumables for investigation | 0 | 20 | 0 |
| NIHR_PRC_015 | Randomisation (manual, IVRS or IWRS) | STUDY TEAM | Randomisation charge per requirement includes allocation of subject number and may be up to 60 mins for oncology studies. Line item is charged per dial in requirement where applicable. Note some studies may require dual dial-in e.g. Pharmacy then clinical staff. Time shown should be adjust to reflect average time required for randomisation. Review of randomisation criteria after run-in period may also be required. | 0 | 15 | 0 |
| NIHR_PRC_016 | Instructions/education for patient and/or care giver | STUDY TEAM | Explaining study procedures to patient and/or care giver, discussion around drug regimen and SAEs. | 15 | 15 | 0 |
| NIHR_PRC_017 | Subject Questionnaire | STUDY TEAM | Variable depending on questionnaire required | 0 | 30 | 0 |
| NIHR_PRC_018 | Review Questionnaire | STUDY TEAM | Variable depending on questionnaire completed | 0 | 30 | 0 |
| NIHR_PRC_019 | Concomitant medication check (at screening) | STUDY TEAM | Complex PD drug regimes may require this procedure | 5 | 15 | 0 |
| NIHR_PRC_020 | Concomitant medication check (on study) | STUDY TEAM | Complex PD drug regimes may require this procedure | 0 | 5 | 0 |
| NIHR_PRC_021 | Prescription for study | STUDY TEAM | 5 | 15 | 0 | |
| NIHR_PRC_022 | Administer study drug in clinic | STUDY TEAM | Variable time depending on study drug administration method required by the protocol. Time should include clinical preparation, administration of study drug and observation. | 15 | 30 | 0 |
| NIHR_PRC_023 | Dispense diaries and instruct | STUDY TEAM | 0 | 15 | 0 | |
| NIHR_PRC_024 | Collect and review diaries | STUDY TEAM | 0 | 15 | 0 | |
| NIHR_PRC_025 | Drug accountability and compliance | STUDY TEAM | Clinical staff responsibility (should not be duplicated with Pharmacy) | 0 | 10 | 0 |
| NIHR_PRC_026 | CRF/eCRF completion including data transfer and query resolution | STUDY TEAM | Variable time depending on amount and type of data collected per visit e.g. complex visit (e.g. Screening or End-of-Study), standard visit or simple visit (e.g. logging phone contact/survival). A time per page to complete approach could be used to calculate actually time needed. Clinicians are usually required to sign off (especially lab results and eCRFs) so clinical time should always be considered. Time includes data query resolution time: calculation of time may require an assumption for the number of queries per patient If required, time should be adjusted to include transfer of patient note information into a Case Report Form (CRF), Electronic Data Capture (EDC) system or and electronic CRF (eCRF) which may include - transcribing into hospital notes and the hospital electronic patient system (if applicable) from one of the sources above - transcribing and reporting of diaries, questionnaires, profiles and titrations. |
15 | 60 | 0 |
| NIHR_PRC_027 | Review/reporting of patient AEs/SAEs | STUDY TEAM | Time allocated per AE/SAE so may require an assumption for the number of AE/SAE per patient or inclusion in the 'Additional Itemised Cost' section instead of 'Per Patient'. Nurse time could be up to 30 for an oncology patient or other complex patient condition studies, which needs to be considered when assigning time. |
5 | 30 | 0 |
| NIHR_PRC_028 | Handover to routine care (End of Trial) | STUDY TEAM | Time for patient study sign-off including letter to Patient's GP and/or handover to routine care. Includes time to confirm if patient completed the study as per the protocol (Y/N) and/or withdrawn (Y/N) | 15 | 0 | 0 |
| NIHR_PRC_029 | Device calibration / alteration of mechanical device settings and monitoring | STUDY TEAM | When devices are used in patient care and integrated into trials, the settings need calibrating, monitoring and altering for the patient | 0 | 40 | 0 |
| NIHR_PRC_030 | Monitoring on-site visits or risk/remote based monitoring communication | STUDY TEAM | Time can be allocated per patient visit which is monitored and is variable depending on duration of the study, requirements of visit and monitoring visit schedule. If inclusion of risk/remote based monitoring communication as an alternative to on-site visits, the monitoring plan should be consulted to ensure monitoring visit frequency and durations are appropriately included. This may be also included in the 'Additional Itemised Cost' section if the monitoring visit frequency is not aligned with patient visits. Clinical time may also be needed for inclusion if requested. As a guidance, CRAs can monitor approximately 10 patient visits at each visit. |
0 | 5 | 0 |
| NIHR_PRC_031 | Dissemination of study results to participants | STUDY TEAM | Investigator time to receive and read the Clinical Study Report (CSR) or synopsis and disseminate the results of the study to the study participants. | 30 | 30 | 0 |
| NIHR_PRC_033 | Dispensing time for standard agent or IMP/NIMP (excluding use of IVR/IWR) | PHARMACY | Pharmacy Activity | 0 | 70 | 0 |
| NIHR_PRC_034 | Aseptic dispensing agent time | PHARMACY | Pharmacy Activity | 0 | 120 | 0 |
| NIHR_PRC_035 | Controlled drug - additional dispensing time | PHARMACY | Pharmacy Activity | 0 | 75 | 0 |
| NIHR_PRC_036 | Advanced therapy - additional preparation time [where relevant] | PHARMACY | Pharmacy Activity | 0 | 240 | 0 |
| NIHR_PRC_037 | Use of IVR/IWR system (only chargeable if performed by Pharmacy) | PHARMACY | Pharmacy Activity | 0 | 16 | 0 |
| NIHR_PRC_038 | Pharmacy arrangement of IMP delivery or posting preparation time to the patient | PHARMACY | Pharmacy Activity | 0 | 20 | 0 |
| NIHR_PRC_039 | Individual patient drug accountability time | PHARMACY | Pharmacy Activity | 0 | 35 | 0 |
| NIHR_PRC_040 | Patient Eligibility Assessment | STUDY TEAM | Time taken to assess the patient against the inclusion, exclusion and medical history criteria for the study | 30 | 0 | 0 |
| NIHR_PRC_041 | ECOG Status | STUDY TEAM | Time taken to assess the patient against the inclusion, exclusion and medical history criteria for the study | 5 | 0 | 0 |
| NIHR_PRC_042 | Pulse Oximetry | STUDY TEAM | Time taken to carry out testing that measures your oxygen saturation level, or the oxygen levels in a recruits blood | 0 | 5 | 0 |
| NIHR_PRC_043 | Reconsenting | STUDY TEAM | Time taken, if necessary, for subjects to reaffirm their decision to participate, to re-consent, or to sign or re-sign a document | 15 | 15 | 0 |
| NIHR_PRC_044 | Monitoring visit (additional itemised cost only) | STUDY TEAM | Time taken for the study team to fully participate in a non-triggered monitoring visit by the trial Sponsor/ CRO | 60 | 240 | 0 |
| Workbook content: | ||||
| This tariff has been created to assist both Industry and NHS partners to create consistent and meaningful costings for Industry sponsored research within the NHS. | ||||
| Values within this tariff do not include the relevant labour time required by research staff to initiate, carry out or report on the activity described. | ||||
| Please note that all values included below are guidelines and may require adaptaion due to complexity, additional staff involvement or eternal third party contracts. | ||||
| All values include an indirect cost and therefore only need the addition of capacity building and the local PbR MFF from the Industry Costing Tool to produce valid figures. | ||||
| All entries contain the following: | ||||
| ● Grantplan or NIHR Coding - Codes from the Industry Grantplan software or NIHR coding (for reference) where Grantplan coding is absent. | ||||
| ● Activity Description - Brief Description of activity taking place | ||||
| ● Specialty - Defined service support specialty that covers the activity (this may vary from one NHS organisation to another. | ||||
| ● Notes - Whether the activity is a single investigation, an intervention with associated investigation or a unit cost activity at setup or during the project. | ||||
| ● 2022/23 Costs - The defined unitary cost for the activity including an indirect element | ||||
| Please note that these are NHS costs only and do not represent costs provided by commercial or academic units. A degree of consideration will be required in order to cost any of these items in conjunction with external NHS SLAs contract to either of these entities. | ||||
| All scanning costs below include a single report witin the unit cost. Additional reports should be requested individually from the reporting section of the tariff | ||||
| Code | Activity Description | Specialty | Notes | 2022/23 |
| 92552 | Pure tone audiometry (threshold); air only | AUDIOLOGY | Investigation | £66 |
| 92553 | Pure tone audiometry (threshold); air and bone | AUDIOLOGY | Investigation | £66 |
| 92555 | Speech audiometry threshold | AUDIOLOGY | Investigation | £86 |
| 92556 | Speech audiometry threshold; with speech recognition | AUDIOLOGY | Investigation | £86 |
| 92557 | Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined) | AUDIOLOGY | Investigation | £122 |
| 92567 | Tympanometry (impedance testing), tympanogram | AUDIOLOGY | Investigation | £43 |
| 92579 | Visual Reinforcement Audiometry (VRA) | AUDIOLOGY | Investigation | £61 |
| 92582 | Conditioning Play Audiometry (CPA) | AUDIOLOGY | Investigation | £61 |
| 92625 | Assessment of tinnitus (includes pitch, loudness matching, and making) | AUDIOLOGY | Investigation | £58 |
| 71275 | CT angiography, chest, without contrast , followed by contrast material and further sections, including image post-processing; MDCT; Multidetector CT: For report use code R1275; (CT Scan) | CARDIOVASCULAR | Investigation | £351 |
| 72159 | Magnetic resonance angiography, spinal canal, spine and contents (MRA), with or without contrast: Reporting code R2159. | CARDIOVASCULAR | Investigation | £606 |
| 75705 | Angiography, angiogram, spinal, selective, spine: Reporting code R5705. If applicable please include code 93539 | CARDIOVASCULAR | Investigation | £2,034 |
| 75710 | Angiography, angiogram, extremity, unilateral: Reporting code R5710. If applicable please include code 93539 | CARDIOVASCULAR | Investigation | £2,034 |
| 75716 | Angiography, angiogram, extremity, bilateral: Reporting code R5716. If applicable please include code 93539 | CARDIOVASCULAR | Investigation | £2,034 |
| 75726 | Angiography, visceral, selective or supraselective, (with or without flush aortogram), radiological supervision and interpretation; For Interpretation and Report used code R5726 | CARDIOVASCULAR | Investigation | £2,034 |
| 75736 | Angiography, angiogram, pelvic, pelvis, selective or supraselective: Reporting code R5736. | CARDIOVASCULAR | Investigation | £2,034 |
| 75741 | Angiography, angiogram, pulmonary, unilateral, selective: Reporting code R5741. | CARDIOVASCULAR | Investigation | £2,034 |
| 75743 | Angiography, angiogram, pulmonary, bilateral, selective: Reporting code R5743. | CARDIOVASCULAR | Investigation | £2,034 |
| 76825 | Fetal Echocardiography, cardiovascular system; real time with image documentation (2D), with or without M-mode recording: Reporting code R6825. | CARDIOVASCULAR | Investigation | £185 |
| 78445 | Non-cardiac vascular flow imaging (ie, angiography, angiogram, venography): Reporting code R8445. | CARDIOVASCULAR | Investigation | £784 |
| 78453 | Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique): Reporting code R8453. | CARDIOVASCULAR | Investigation | £650 |
| 78454 | Myocardial perfusion imaging, multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection: Reporting code R8454. | CARDIOVASCULAR | Investigation | £650 |
| 78472 | Cardiac blood pool imaging, radionuclide ventriculography, left ventricular ejection fraction (LVEF) (RNV) (MUGA), single study at rest or stress: Reporting code R8472. | CARDIOVASCULAR | Investigation | £458 |
| 78473 | Cardiac blood pool imaging, radionuclide ventriculography, left ventricular ejection fraction (LVEF) (RNV) (MUGA), multiple studies at rest and stress: Reporting code R8473. | CARDIOVASCULAR | Investigation | £458 |
| 92230 | Fluorescein angioscopy, angiogram; unilateral: Includes interpretation and report | CARDIOVASCULAR | Investigation | £784 |
| 93000 | Electrocardiogram, routine ECG (EKG) with at least 12 leads, 12 lead ECG, 12-lead ECG: Includes tracing, interpretation and report | CARDIOVASCULAR | Investigation | £34 |
| 93005 | Electrocardiogram, routine ECG (EKG) with at least 12 leads, 12 lead ECG, 12-lead ECG: Tracing only | CARDIOVASCULAR | Investigation | £22 |
| 93010 | Electrocardiogram, routine ECG (EKG) with at least 12 leads, 12 lead ECG, 12-lead ECG: Interpretation and report only | CARDIOVASCULAR | Investigation | £34 |
| 93015 | Cardiovascular stress test using treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress (ETT); with physician supervision, interpretation and report | CARDIOVASCULAR | Investigation | £241 |
| 93016 | Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress | CARDIOVASCULAR | Investigation | £241 |
| 93040 | Rhythm electrocardiogram, one to three leads (ECG) (EKG); with tracing, interpretation and report | CARDIOVASCULAR | Investigation | £34 |
| 93224 | External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, physician review and interpretation | CARDIOVASCULAR | Investigation | £34 |
| 93225 | Electrocardiographic monitoring for up to 48 hours by continuous original ECG waveform recording and storage, holter monitoring; recording which includes hook-up, recording, and disconnection | CARDIOVASCULAR | Investigation | £168 |
| 93226 | Electrocardiographic monitoring for up to 48 hours by continuous original ECG waveform recording and storage, holter monitoring; scanning analysis with report, up to 48 hours | CARDIOVASCULAR | Investigation | £168 |
| 93227 | Electrocardiographic monitoring for up to 48 hours by continuous original ECG waveform recording and storage, holter monitoring; physician review and interpretation only, up to 48 hours | CARDIOVASCULAR | Investigation | £168 |
| 93278 | Signal-averaged electrocardiography (SAECG), with or without ECG | CARDIOVASCULAR | Investigation | £30 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation (2D) , includes M-mode recording with spectral or color flow Doppler echocardiography: Reporting code R3306 | CARDIOVASCULAR | Investigation | £221 |
| 93307 | Echocardiography, transthoracic, real-time with image documentation (2D) with or without M-mode recording; complete: Reporting code R3307. | CARDIOVASCULAR | Investigation | £221 |
| 93308 | Echocardiography, transthoracic, real-time with image documentation (2D) with or without M-mode recording; follow-up or limited study: Reporting code R3308. | CARDIOVASCULAR | Investigation | £221 |
| 93312 | Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement under sedation, image acquisition, interpretation and report | CARDIOVASCULAR | Investigation | £694 |
| 93320 | Doppler echocardiography, pulsed wave and/or continuous wave with spectral display; complete | CARDIOVASCULAR | Investigation | £221 |
| 93321 | Doppler echocardiography, pulsed wave and/or continuous wave with spectral display; follow-up or limited study | CARDIOVASCULAR | Investigation | £221 |
| 93325 | Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | CARDIOVASCULAR | Investigation | £221 |
| 93350 | Echocardiography, transthoracic, real-time with image documentation (2D, +/- M-mode recording), during rest and cardiovascular stress test , for interpretation and report please use code R3350. | CARDIOVASCULAR | Investigation | £221 |
| 93464 | Physiological exercise study (eg, bicycle or arm ergometry) including assessing hemodynamic measurements before and after moderate sedation: Reporting code R3464 | CARDIOVASCULAR | Investigation | £241 |
| 93660 | Evaluation of cardiovascular function with tilt table evaluation, with continuous ECG monitoring and intermittent blood pressure monitoring with or without pharmacological intervention | CARDIOVASCULAR | Investigation | £597 |
| 93662 | Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation ; Reporting code R3662. | CARDIOVASCULAR | Investigation | £185 |
| 94620 | Pulmonary stress testing; simple (eg, prolonged exercise test for bronchospasm with pre- and post-spirometry): Reporting code R4620. | CARDIOVASCULAR | Investigation | £309 |
| 94621 | Pulmonary stress testing; complex including measurements of CO2 production, O2 uptake and electrocardiographic recordings: Reporting code R4621. | CARDIOVASCULAR | Investigation | £309 |
| NIHR_INV_004 | Insertion of Sheath Radial | CARDIOVASCULAR | Intervention includes Investigation (where applicable) | £967 |
| NIHR_INV_005 | Insertion of Sheath (Femoral) - Short | CARDIOVASCULAR | Intervention includes Investigation (where applicable) | £951 |
| NIHR_INV_006 | Insertion of Sheath (Femoral) - Long | CARDIOVASCULAR | Intervention includes Investigation (where applicable) | £987 |
| NIHR_INV_007 | Insertion of PCI wire | CARDIOVASCULAR | Intervention includes Investigation (where applicable) | £1,006 |
| NIHR_INV_008 | Insertion of OCT Catheter | CARDIOVASCULAR | Intervention includes Investigation (where applicable) | £1,833 |
| NIHR_INV_009 | IVUS | CARDIOVASCULAR | Investigation | £193 |
| NIHR_INV_010 | 24 Hour Ambulatory ECG Monitor | CARDIOVASCULAR | Investigation | £126 |
| NIHR_INV_011 | 48 Hour Ambulatory ECG Monitor | CARDIOVASCULAR | Investigation | £104 |
| NIHR_INV_012 | Tape Analysis | CARDIOVASCULAR | Investigation | £244 |
| NIHR_INV_013 | 24 Hour Blood Pressure Monitor | CARDIOVASCULAR | Investigation | £61 |
| NIHR_INV_014 | Echocardiogram with Doppler | CARDIOVASCULAR | Investigation | £506 |
| NIHR_INV_015 | Metabolic Exercise Test | CARDIOVASCULAR | Investigation | £462 |
| NIHR_INV_016 | Reveal Interrogation | CARDIOVASCULAR | Investigation | £244 |
| NIHR_INV_018 | Pacemaker Check | CARDIOVASCULAR | Investigation | £133 |
| NIHR_INV_019 | ICD Check | CARDIOVASCULAR | Investigation | £133 |
| NIHR_INV_020 | Arjalamine Test | CARDIOVASCULAR | Investigation | £395 |
| NIHR_INV_022 | Stress Echo | CARDIOVASCULAR | Investigation | £400 |
| NIHR_INV_023 | Contrast Echo | CARDIOVASCULAR | Investigation | £891 |
| NIHR_INV_024 | Biventricular Pacemaker Assessments and Optimisations via Echocardiogram | CARDIOVASCULAR | Investigation | £891 |
| T1206 | Electrocardiogram, 12 Lead ECG - Triplicate; Includes tracing, interpretation and report | CARDIOVASCULAR | Investigation | £34 |
| T1207 | Electrocardiogram, 12 Lead ECG - Triplicate; tracing only; Reporting code RT207 | CARDIOVASCULAR | Investigation | £30 |
| T5744 | Angiography, angiogram, complete coronary: Reporting code RT744. (Formerly QuintilesIMS code 75744) | CARDIOVASCULAR | Investigation | £784 |
| NIHR_INV_084 | Cone Beam CT | DENTAL RADIOLOGY | Investigation | £169 |
| NIHR_INV_001 | Daily Facility Charge - Per Day (PAEDIATRIC) | GENERAL | Setup or Additional Itemised Activity | £620 |
| NIHR_INV_002 | Overnight Facility Charge, Simple (e.g. regular ward room) - Per Night (PAEDIATRIC) | GENERAL | Setup or Additional Itemised Activity | £871 |
| NIHR_INV_003 | Overnight Facility Charge, High (e.g. high dependancy unit, CCU, psychiatric medium secure unit) - Per Night | GENERAL | Setup or Additional Itemised Activity | £1,792 |
| NP009 | Daily Facility Charge - Per Day (ADULT) | GENERAL | Setup or Additional Itemised Activity | £215 |
| NP010 | Overnight Facility Charge, Simple (e.g. regular ward room) - Per Night (ADULT) | GENERAL | Setup or Additional Itemised Activity | £427 |
| NP013 | Copies of Diagnostic Films, Simple (e.g. x-rays) - Per Copy | GENERAL | Setup or Additional Itemised Activity | £56 |
| NP014 | Copies of Diagnostic Films, Complex (e.g. high technology, video recordings, compact discs, CDs) - Per Copy | GENERAL | Setup or Additional Itemised Activity | £56 |
| NP016 | Overnight Facility Charge, Complex (e.g. intensive care unit, telemetry unit, psychiatric hospital) - Per Night | GENERAL | Setup or Additional Itemised Activity | £3,096 |
| OC057 | Electronic Lab Data Transfer - Per Transfer | GENERAL | Setup or Additional Itemised Activity | £29 |
| OC059 | Lab Set-Up Costs, Laboratory Set-Up Costs - Per Lab | GENERAL | Setup or Additional Itemised Activity | £276 |
| 81161 | DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis and duplication analysis, if performed | GENETICS | Investigation | £389 |
| 81200 | ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X) | GENETICS | Investigation | £389 |
| 81201 | APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence | GENETICS | Investigation | £389 |
| 81202 | APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants | GENETICS | Investigation | £389 |
| 81203 | APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81205 | BCKDHB (branched-chain keto acid dehydrogenase E1,beta polypeptide) (eg, Maple syrup urine disease) gene analysis, common variants (eg, R183P, G278S, E422X) | GENETICS | Investigation | £389 |
| 81206 | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative | GENETICS | Investigation | £389 |
| 81207 | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative | GENETICS | Investigation | £389 |
| 81208 | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative | GENETICS | Investigation | £389 |
| 81209 | BLM (Bloom syndrome, RecQ helicase-like) (eg, Bloom syndrome) gene analysis, 2281del6ins7 variant | GENETICS | Investigation | £389 |
| 81210 | BRAF (v-raf murine sarcoma viral oncogene homolog B1) (eg, colon cancer), gene analysis, V600E variant | GENETICS | Investigation | £389 |
| 81211 | BRCA1, BRCA2 gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 | GENETICS | Investigation | £389 |
| 81212 | BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis;185delAG, 5385insC, 6174delT variants | GENETICS | Investigation | £389 |
| 81213 | BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants | GENETICS | Investigation | £389 |
| 81214 | BRCA1 gene analysis; full sequence analysis and common duplication/deletion variants | GENETICS | Investigation | £389 |
| 81215 | BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant | GENETICS | Investigation | £389 |
| 81216 | BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81217 | BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant | GENETICS | Investigation | £389 |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, ACMG/ACOG guidelines) | GENETICS | Investigation | £389 |
| 81221 | CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants | GENETICS | Investigation | £389 |
| 81222 | CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81224 | CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility) | GENETICS | Investigation | £389 |
| 81225 | CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17) | GENETICS | Investigation | £389 |
| 81226 | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN) | GENETICS | Investigation | £389 |
| 81227 | CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6) | GENETICS | Investigation | £389 |
| 81228 | Cytogenomic constitutional microarray analysis; interrogation of genomic regions for copy number variants | GENETICS | Investigation | £389 |
| 81229 | Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities | GENETICS | Investigation | £389 |
| 81235 | EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G749A, G719S, L861Q) (formerly code T0910) | GENETICS | Investigation | £389 |
| 81241 | F5 (coagulation Factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant | GENETICS | Investigation | £389 |
| 81242 | FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis, common variant (eg, IVS4 4A>T) | GENETICS | Investigation | £389 |
| 81243 | FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles | GENETICS | Investigation | £389 |
| 81244 | FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status) | GENETICS | Investigation | £389 |
| 81251 | GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2 1G>A) | GENETICS | Investigation | £389 |
| 81255 | HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, common variants (eg, 1278insTATC, 1421 1G>C, G269S) | GENETICS | Investigation | £389 |
| 81256 | HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C282Y, H63D) | GENETICS | Investigation | £389 |
| 81257 | HBA1/HBA2 gene analysis, for common deletions or variant | GENETICS | Investigation | £389 |
| 81261 | IGH@ gene rearrangement analysis to detect abnormal clonal populations; amplified methodology | GENETICS | Investigation | £389 |
| 81262 | IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot) | GENETICS | Investigation | £389 |
| 81263 | IGH@ (Immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, B-cell), variable region somatic mutation analysis | GENETICS | Investigation | £389 |
| 81264 | IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) | GENETICS | Investigation | £389 |
| 81265 | Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen | GENETICS | Investigation | £389 |
| 81266 | Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen | GENETICS | Investigation | £389 |
| 81267 | Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection | GENETICS | Investigation | £389 |
| 81268 | Chimerism analysis, post transplantation specimen, includes comparison to previously performed baseline analyses; with cell selection each cell type | GENETICS | Investigation | £389 |
| 81275 | KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene) (eg, carcinoma) gene analysis, variants in codons 12 and 13 | GENETICS | Investigation | £389 |
| 81276 | KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146) | GENETICS | Investigation | £389 |
| 81290 | MCOLN1 (mucolipin 1) (eg, Mucolipidosis, type IV) gene analysis, common variants (eg, IVS3-2A>G, del6.4kb) | GENETICS | Investigation | £389 |
| 81291 | MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C) | GENETICS | Investigation | £389 |
| 81292 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81293 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | GENETICS | Investigation | £389 |
| 81294 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81295 | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81296 | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | GENETICS | Investigation | £389 |
| 81297 | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81298 | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary nonpolyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81299 | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary nonpolyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | GENETICS | Investigation | £389 |
| 81300 | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary nonpolyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81301 | Microsatellite instability analysis of markers for mismatch repair deficiency, includes comparison of neoplastic and normal tissue, if performed | GENETICS | Investigation | £389 |
| 81302 | MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81303 | MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant | GENETICS | Investigation | £389 |
| 81304 | MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81310 | NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants | GENETICS | Investigation | £389 |
| 81311 | NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61) | GENETICS | Investigation | £389 |
| 81313 | PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (eg, prostate cancer) | GENETICS | Investigation | £389 |
| 81315 | PML/RARalpha, (t(15;17)), (promyelocytic leukemia/ retinoic acid receptor alpha) translocation analysis; common breakpoints, qualitative or quantitative | GENETICS | Investigation | £389 |
| 81316 | PML/RARalpha, (t(15;17)), (promyelocytic leukemia/ retinoic acid receptor alpha) translocation analysis; single breakpoint, qualitative or quantitative | GENETICS | Investigation | £389 |
| 81317 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81318 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | GENETICS | Investigation | £389 |
| 81319 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | GENETICS | Investigation | £389 |
| 81321 | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81322 | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant | GENETICS | Investigation | £389 |
| 81323 | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant | GENETICS | Investigation | £389 |
| 81324 | PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81325 | PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis | GENETICS | Investigation | £389 |
| 81326 | PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant | GENETICS | Investigation | £389 |
| 81327 | Molecular PathologyRevisions have been made to Molecular Pathology Guidelines including the deletion of three Tier 1 Molecular Pathology CPT codes (81280-81282) and the addition of a new Tier 1 CPT c | GENETICS | Investigation | £389 |
| 81330 | SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, Niemann-Pick disease, Type A) gene analysis, common variants (eg, R496L, L302P, fsP330) | GENETICS | Investigation | £389 |
| 81331 | SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis | GENETICS | Investigation | £389 |
| 81332 | SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common variants (eg, *S and *Z) | GENETICS | Investigation | £389 |
| 81340 | TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction) | GENETICS | Investigation | £389 |
| 81341 | TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot) | GENETICS | Investigation | £389 |
| 81342 | TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) | GENETICS | Investigation | £389 |
| 81350 | UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37) | GENETICS | Investigation | £389 |
| 81355 | VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variants (eg, -1639/3673) | GENETICS | Investigation | £389 |
| 81370 | HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 | GENETICS | Investigation | £389 |
| 81371 | HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, and -DRB1/3/4/5 (eg, verification typing) | GENETICS | Investigation | £389 |
| 81372 | HLA Class I typing, low resolution (eg, antigen equivalents); complete (ie, HLA-A, -B, and -C) | GENETICS | Investigation | £389 |
| 81373 | HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each | GENETICS | Investigation | £389 |
| 81374 | HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each | GENETICS | Investigation | £389 |
| 81375 | HLA Class II typing, low resolution (eg, antigen equivalents); HLADRB1/3/4/5 and -DQB1 | GENETICS | Investigation | £389 |
| 81376 | HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1 /3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each | GENETICS | Investigation | £389 |
| 81377 | HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each | GENETICS | Investigation | £389 |
| 81378 | HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLAA, -B, -C, and -DRB1 | GENETICS | Investigation | £389 |
| 81379 | HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and -C) | GENETICS | Investigation | £389 |
| 81380 | HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each | GENETICS | Investigation | £389 |
| 81381 | HLA Class I typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, B*57:01P), each | GENETICS | Investigation | £389 |
| 81382 | HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQB1, -DQA1, -DPB1, or -DPA1), each | GENETICS | Investigation | £389 |
| 81383 | HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each | GENETICS | Investigation | £389 |
| 81400 | Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis) | GENETICS | Investigation | £389 |
| 81402 | Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants immunoglobulin and T-cell receptor gene rearrangements) | GENETICS | Investigation | £389 |
| 81400-01 | ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD), K304E variant New molecular pathology code benchmarks pending increased market usage. | GENETICS | Investigation | £389 |
| 81400-02 | ACE (angiotensin converting enzyme), insertion/deletion variant. New molecular pathology code benchmarks pending increased market usage. | GENETICS | Investigation | £389 |
| 81400-03 | AGTR1 (angiotensin II receptor, type 1) (eg, essential hypertension),1166A>C variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-04 | BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide), Y438N variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-05 | CCR5 (chemokine C-C motif receptor 5), 32-bpdeletion mutation/794 825del32 deletion. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-06 | CLRN1 (clarin 1) (eg, Usher syndrome, type 3), N48K variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-07 | DPYD (dihydropyrimidine dehydrogenase), IVS14+1G>A variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-08 | F2 (coagulation factor 2) (eg, hereditary hypercoagulability), 1199G>Avariant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-09 | F5 (coagulation factor V) (eg, hereditary hypercoagulability), HR2 variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-10 | F13B (coagulation factor XIII, B polypeptide), V34L variant . New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-13 | FGFR1 (fibroblast growth factor receptor 1), P252R variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-14 | FGFR3 (fibroblast growth factor receptor 3) (eg, Muenke syndrome),P250R variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-15 | FKTN (Fukutin) retrotransposon insertion variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-25 | IL28B (interleukin 28B [interferon, lambda 3]) (eg, drug response), rs12979860 variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-26 | IVD (isovaleryl-CoA dehydrogenase) (eg, isovaleric acidemia), A282Vvariant | GENETICS | Investigation | £389 |
| 81400-28 | NEB (nebulin) (eg, nemaline myopathy 2), exon 55 deletion variant | GENETICS | Investigation | £389 |
| 81400-29 | PCDH15 (protocadherin-related 15) (eg, Usher syndrome type 1F), R245X variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-30 | SERPINE1 (serpine peptidase inhibitor clade E, member 1, plasminogen activator inhibitor -1, PAI-1), 4G variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-31 | SHOC2 (soc-2 suppressor of clear homolog) (eg, Noonan-like syndromewith loose anagen hair), S2G variant | GENETICS | Investigation | £389 |
| 81400-32 | SLCO1B1 (solute carrier organic anion transporter family, member 1B1), V174A variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81400-33 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscularatrophy), exon 7 deletion | GENETICS | Investigation | £389 |
| 81400-34 | SRY (sex determining region Y) (eg, 46,XX testicular disorder of sexdevelopment, gonadal dysgenesis), gene analysis | GENETICS | Investigation | £389 |
| 81400-35 | TOR1A (torsin family 1, member A [torsin A])(eg, early-onset primarydystonia [DYT1]), 907_909delGAG (904_906delGAG) variant. New molecular pathology code benchmarks pending increased market usage. . | GENETICS | Investigation | £389 |
| 81401-01 | ABCC8 (ATP-binding cassette, sub-family C CFTR/MRP], member 8) common variants | GENETICS | Investigation | £389 |
| 81401-03 | ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg, K304E, Y42H). | GENETICS | Investigation | £389 |
| 81401-05 | AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles | GENETICS | Investigation | £389 |
| 81401-07 | APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, *2, *3, *4) | GENETICS | Investigation | £389 |
| 81401-08 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded size or methylation status) | GENETICS | Investigation | £389 |
| 81401-09 | ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy),evaluation to detect abnormal (eg, expanded) alleles. | GENETICS | Investigation | £389 |
| 81401-10 | ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detectabnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-11 | ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detectabnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-12 | ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation to detect abnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-13 | ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detectabnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-14 | ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg,expanded) alleles. | GENETICS | Investigation | £389 |
| 81401-15 | ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detectabnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-16 | CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha1A subunit) (eg, spinocerebellar ataxia), evaluation to detectabnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-17 | CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative,and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-18 | CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathioninebeta-synthase deficiency), common variants (eg, I278T, G307S). | GENETICS | Investigation | £389 |
| 81401-19 | CCND1/IGH (BCL1/IgH, t(11;14)) (eg, mantle cell lymphoma)translocation analysis, major breakpoint, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-20 | CFH/ARMS2 (complement factor H/age-related maculopathysusceptibility 2) (eg, macular degeneration), common variants(eg, Y402H [CFH], A69S [ARMS2]). | GENETICS | Investigation | £389 |
| 81401-21 | CNBP (CCHC-type zinc finger, nucleic acid binding protein)(eg, myotonic dystrophy type 2), evaluation to detectabnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-22 | CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease),evaluation to detect abnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-23 | CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) | GENETICS | Investigation | £389 |
| 81401-24 | CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg,drug metabolism), common variants (eg, *2, *3, *4, *5, *6). | GENETICS | Investigation | £389 |
| 81401-26 | E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocationanalysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-27 | EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis. | GENETICS | Investigation | £389 |
| 81401-28 | ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-29 | ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-30 | EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-31 | EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermaltumor), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-32 | EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermaltumor), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-33 | EWSR1/WT1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor desmoplastic small round cell tumor), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-34 | F11 (coagulation factor XI) (eg, coagulation disorder), common variants(eg, E117X [Type II], F283L [Type III], IVS14del14, and IVS14+1G>A[Type I]). | GENETICS | Investigation | £389 |
| 81401-35 | FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,1620C>A, 1620C>G). | GENETICS | Investigation | £389 |
| 81401-36 | FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilicleukemia), qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-37 | FLG (filaggrin) (eg, icthyosis vulgaris), common variants (eg, R501X, 2282del4, R2447X, S3247X, 3702delG). | GENETICS | Investigation | £389 |
| 81401-38 | FOXO1/PAX3 t(12;13)) (eg, alveolar rhabdomyosarcoma), translocation analysis, qualitative, and quantitative, if performed | GENETICS | Investigation | £389 |
| 81401-39 | FOXO1/PAX7 (t(21;13)) (eg, alveolar rhabdomyosarcoma), translocation analysis, qualitative, and quantitative, if performed | GENETICS | Investigation | £389 |
| 81401-40 | FXN (frataxin) (eg, Friedreich ataxia), evaluation to detect abnormal(expanded) alleles. | GENETICS | Investigation | £389 |
| 81401-41 | FUS/DDIT3 (t(12;16)) (eg, myxoid liposarcoma), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-42 | GALC (galactosylceramidase) (eg, Krabbe disease), common variants (eg,c.857G>A, 30-kb deletion) | GENETICS | Investigation | £389 |
| 81401-43 | GALT (galactose-1-phosphate uridylyltransferase) (eg, galactosemia), common variants (eg, Q188R, S135L, K285N, T138M, L195P, Y209C, IVS2-2A>G, P171S, del5kb, N314D, L218L/N314D) | GENETICS | Investigation | £389 |
| 81401-44 | GNAQ (guanine nucleotide-binding protein G[q] subunit alpha)(eg, uveal melanoma), common variants (eg, R183, Q209) . | GENETICS | Investigation | £389 |
| 81401-45 | GALT (galactose-1-phosphate uridylyltransferase) (eg, galactosemia),common variants (eg, Q188R, S135L, K285N, T138M, L195P, Y209C, IVS2-2A>G, P171S, del5kb, N314D, L218L/N314D). | GENETICS | Investigation | £389 |
| 81401-46 | GNAQ (guanine nucleotide-binding protein G[q] subunit alpha)(eg, uveal melanoma), common variants (eg, R183, Q209). | GENETICS | Investigation | £389 |
| 81401-47 | H19 (imprinted maternally expressed transcript [non-protein coding])(eg, Beckwith-Wiedemann syndrome), methylation analysis. | GENETICS | Investigation | £389 |
| 81401-48 | HBB (hemoglobin, beta) (eg, sickle cell anemia, hemoglobin C,hemoglobin E), common variants (eg, HbS, HbC, HbE) | GENETICS | Investigation | £389 |
| 81401-49 | HTT (huntingtin) (eg, Huntington disease), evaluation to detect abnormal(eg, expanded) alleles | GENETICS | Investigation | £389 |
| 81401-50 | KCNQ1OT1 (KCNQ1 overlapping transcript 1 [non-protein coding]) (eg, Beckwith-Wiedemann syndrome), methylation analysis. | GENETICS | Investigation | £389 |
| 81401-52 | ont. MED12 (mediator complex subunit 12) (eg, FG syndrome type 1, Lujansyndrome), common variants (eg, R961W, N1007S). | GENETICS | Investigation | £389 |
| 81401-53 | MEG3/DLK1 (maternally expressed 3 [non-protein coding]/delta-like 1homolog [Drosophila]) (eg,intrauterine growth retardation), methylation analysis. | GENETICS | Investigation | £389 |
| 81401-54 | MLL/AFF1 (t(4;11)) (eg, acute lymphoblastic leukemia), translocationanalysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-55 | MLL/MLLT3 (t(9;11)) (eg, acute myeloid leukemia), translocationanalysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-56 | MT-RNR1 (mitochondrially encoded 12S RNA) (eg, nonsyndromichearing loss), common variants (eg, m.1555A>G, m.1494C>T). | GENETICS | Investigation | £389 |
| 81401-57 | MUTYH (mutY homolog [E. coli]) (eg, MYH-associated polyposis),common variants (eg, Y165C, G382D). | GENETICS | Investigation | £389 |
| 81401-58 | MT-ATP6 (mitochondrially encoded ATP synthase 6) (eg, neuropathy with ataxia and retinitis pigmentosa [NARP], Leigh syndrome), commonvariants (eg, m.8993T>G, m.8993T>C). | GENETICS | Investigation | £389 |
| 81401-59 | MT-ND4, MT-ND6 (mitochondrially encoded NADH dehydrogenase4, mitochondrially encoded NADH dehydrogenase 6) common variants | GENETICS | Investigation | £389 |
| 81401-60 | MT-TK (mitochondrially encoded tRNA lysine) (eg, myoclonic epilepsywith ragged-red fibers [MERRF]), common variants (eg, m.8344A>G,m.8356T>C). | GENETICS | Investigation | £389 |
| 81401-61 | MT-TL1 (mitochondrially encoded tRNA leucine 1 [UUA/G]) (eg, diabetesand hearing loss), common variants (eg, m.3243A>G, m.14709 T>C). | GENETICS | Investigation | £389 |
| 81401-62 | MT-ND5 (mitochondrially encoded tRNA leucine 1 [UUA/G],mitochondrially encoded NADH dehydrogenase 5) mitochondrial encephalopathy with lactic acidosis and stroke-like episodes [MELAS]),common variants | GENETICS | Investigation | £389 |
| 81401-63 | MT-TS1, MT-RNR1 (mitochondrially encoded tRNA serine 1 [UCN],mitochondrially encoded 12S RNA) ,common variants | GENETICS | Investigation | £389 |
| 81401-64 | NOD2 (nucleotide-binding oligomerization domaincontaining 2) (eg, Crohn’s disease, Blau syndrome),common variants (eg, SNP 8, SNP 12, SNP 13). | GENETICS | Investigation | £389 |
| 81401-65 | NPM1/ALK (t(2;5)) (eg, anaplastic large cell lymphoma),translocation analysis. | GENETICS | Investigation | £389 |
| 81401-66 | PABPN1 (poly[A] binding protein, nuclear 1) (eg, oculopharyngealmuscular dystrophy), evaluation to detect abnormal (eg, expanded) alleles. | GENETICS | Investigation | £389 |
| 81401-68 | PPP2R2B (protein phosphatase 2, regulatory subunit B, beta) (eg,spinocerebellar ataxia), evaluation to detect abnormal(eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-69 | PRSS1 (protease, serine, 1 [trypsin 1]) (eg, hereditary pancreatitis),common variants (eg, N29I, A16V,R122H) | GENETICS | Investigation | £389 |
| 81401-70 | PYGM (phosphorylase, glycogen, muscle) (eg, glycogen storage diseasetype V, McArdle disease), common variants (eg, R50X, G205S). | GENETICS | Investigation | £389 |
| 81401-71 | RUNX1/RUNX1T1 (t(8;21)) (eg, acute myeloid leukemia) translocationanalysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-72 | SEPT9 (Septin 9) (eg, colon cancer), methylation analysis. | GENETICS | Investigation | £389 |
| 81401-73 | SMN1/SMN2 (survival of motor neuron 1, telomeric/survival of motorneuron 2, centromeric) (eg,spinal muscular atrophy), dosage analysis (eg,carrier testing). | GENETICS | Investigation | £389 |
| 81401-74 | SS18/SSX1 (t(X;18)) (eg, synovial sarcoma), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-75 | SS18/SSX2 (t(X;18)) (eg, synovial sarcoma), translocation analysis, qualitative, and quantitative, if performed. | GENETICS | Investigation | £389 |
| 81401-76 | TBP (TATA box binding protein) (eg, spinocerebellar ataxia), evaluation todetect abnormal (eg, expanded) alleles . | GENETICS | Investigation | £389 |
| 81401-77 | TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), common variants (eg, *2, *3) | GENETICS | Investigation | £389 |
| 81401-78 | TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drugmetabolism), tandem repeat variant. | GENETICS | Investigation | £389 |
| 81401-79 | VWF (von Willebrand factor) (eg, von Willebrand disease type 2N), common variants (eg, T791M, R816W, R854Q) | GENETICS | Investigation | £389 |
| 81402-01 | Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69)(eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity). Please reference general code 81402. | GENETICS | Investigation | £389 |
| 81402-02 | COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed. Please reference general code 81402. | GENETICS | Investigation | £389 |
| 81402-03 | CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2), common variants | GENETICS | Investigation | £389 |
| 81402-05 | IGH@/BCL2 (t(14;18)) translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr)breakpoints, qualitative or quantitative. Please reference general code 81402. | GENETICS | Investigation | £389 |
| 81402-06 | KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), common variants (eg, D816V, D816Y, D816F) | GENETICS | Investigation | £389 |
| 81402-07 | MEFV (Mediterranean fever) (eg, familial Mediterranean fever),common variants (eg, E148Q, P369S,F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H). Please reference general code 81402. | GENETICS | Investigation | £389 |
| 81402-08 | MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg,myeloproliferative disorder), common variants (eg,W515A, W515K, W515L, W515R). Please reference general code 81402. | GENETICS | Investigation | £389 |
| 81402-09 | TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population. Please reference general code 81402. | GENETICS | Investigation | £389 |
| 81402-10 | Uniparental disomy (UPD) (eg, Russell-Silver syndrome, PraderWilli/Angelman syndrome), short tandem repeat (STR) analysis | GENETICS | Investigation | £389 |
| 81403-03 | ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), duplication/deletionanalysis | GENETICS | Investigation | £389 |
| 81403-05 | CEL (carboxyl ester lipase [bile salt-stimulated lipase]), targeted sequence analysis ofexon 11 | GENETICS | Investigation | £389 |
| 81403-06 | CTNNB1 (catenin [cadherin-associated protein], beta 1, 88kDa) (eg, desmoid tumors), targeted sequence analysis (eg, exon 3). Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-07 | DAZ/SRY (deleted in azoospermia and sex determining region Y)(eg, male infertility), common deletions(eg, AZFa, AZFb, AZFc, AZFd). Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-09 | EPCAM (epithelial cell adhesion molecule) (eg, Lynch syndrome), duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81403-10 | F8 (coagulation factor VIII) (eg, hemophilia A), inversion analysis, intron 1and intron 22A | GENETICS | Investigation | £389 |
| 81403-11 | F12 (coagulation factor XII [Hageman factor]) (eg, angioedema, hereditary, type III; factorXII deficiency), targeted sequence analysis of exon 9. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-12 | FGFR3 (fibroblast growth factor receptor 3) (eg, isolated craniosynostosis), targeted sequence analysis (eg, exon 7) | GENETICS | Investigation | £389 |
| 81403-14 | HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia),duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81403-15 | HRAS (v-Ha-ras Harvey ratsarcoma viral oncogene homolog) (eg,Costello syndrome), exon 2 Sequence. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-16 | IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma),common exon 4 variants (eg, R132H,R132C) | GENETICS | Investigation | £389 |
| 81403-17 | IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma),common exon 4 variants (eg,R140W, R172M). Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-19 | KCNC3 (potassium voltage-gated channel, Shaw-related subfamily,member 3) (eg, spinocerebellar ataxia), targeted sequence analysis(eg, exon 2) . Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-22 | Killer cell immunoglobulin-like receptor (KIR) genefamily (eg, hematopoietic stem cell transplantation), genotyping of KIR family genes. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-24 | KRAS (v-Ki-ras2 Kirsten ratsarcoma viral oncogene) (eg, carcinoma),gene analysis, variant(s) in exon 3 (eg, codon 61) | GENETICS | Investigation | £389 |
| 81403-26 | MICA (MHC class I polypeptide-related sequence A) (eg, solidorgan transplantation), common variants (eg, *001, *002). Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-27 | MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg,myeloproliferative disorder), exon 10 sequence | GENETICS | Investigation | £389 |
| 81403-30 | NDP (Norrie disease [pseudoglioma]) (eg, Norrie disease),duplication/deletion analysis. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-32 | PHOX2B (paired-like homeobox 2b) (eg, congenital central hypoventilation syndrome), duplication/deletionanalysis. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-34 | SH2D1A (SH2 domain containing 1A) (eg, X-linked lymphoproliferativesyndrome), duplication/deletion analysis. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-35 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscularatrophy), known familialsequence variant(s). Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-36 | TWIST1 (twist homolog 1 [Drosophila]) (eg, Saethre-Chotzen syndrome), duplication/deletion analysis. Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-37 | UBA1 (ubiquitin-like modifier activating enzyme 1) (eg, spinal muscularatrophy, X-linked), targeted sequence analysis(eg, exon 15) . Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81403-38 | VHL (von Hippel-Lindau tumor suppressor) (eg, von Hippel-Lindau familial cancer syndrome), deletion/duplication analysis | GENETICS | Investigation | £389 |
| 81403-39 | VWF (von Willebrand factor) (eg, von Willebrand disease types 2A, 2B,2M), targeted sequence analysis (eg, exon 28). Please reference general code 81403. | GENETICS | Investigation | £389 |
| 81404-01 | ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg,exons 5 and 6). Please reference general code 81404. | GENETICS | Investigation | £389 |
| 81404-02 | AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), characterization of alleles (eg, expandedsize and methylation status). Please reference general code 81404. | GENETICS | Investigation | £389 |
| 81406-28 | COL6A2 (collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81406-31 | CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome),duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81406-32 | Cytogenomic microarray analysis, neoplasia (eg, interrogation of copynumber microarray analysis) | GENETICS | Investigation | £389 |
| 81406-45 | F8 (coagulation factor VIII) (eg, hemophilia A), duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81406-68 | JAG1 (jagged 1) (eg, Alagille syndrome), duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81406-95 | OPA1 (optic atrophy 1) (eg, optic atrophy), duplication/deletion analysis | GENETICS | Investigation | £389 |
| 81401 | Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [using nonsequencing target variant analysis], or detection of a dynamic mutation disorder) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 83516 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen, qualitative or semiquantitative; multiple step method | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 83518 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, single step method (eg, reagent strip) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative use for all interleukin and cytokine analysis; thromin-Antithrombin Complex; Cystatin C | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86021 | Antibody identification; leukocyte antibodies | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86022 | Antibody identification; platelet antibodies | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86023 | Antibody identification; platelet associated immunoglobulin assay | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86147 | Cardiolipin (phospholipid) antibody, antiphospholipid, each Ig class | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86200 | Cyclic citrullinated peptide (CCP), antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86215 | Deoxyribonuclease, antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86235 | Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SSA, SS-B, SSB, Sm, RNP, Sc170, J01); each antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86255 | Fluorescent noninfectious agent antibody;anti-smooth muscle antibody (SMA) or anti-mitochondrial antibody; each antibody (e.g. anti-neutrophil cytoplasmic antibodies (ANCA)) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86256 | Fluorescent noninfectious agent antibody; titer, each antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86277 | Growth hormone, human (HGH), antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86341 | Islet cell antibody, Anti-islet antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86352 | Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP); (Formerly QuintilesIMS code TM012) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 86403 | Particle agglutination; screen, each antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86406 | Particle agglutination; titer, each antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86590 | Streptokinase, antibody | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86602 | Antibody; actinomyces | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86603 | Antibody; adenovirus | IMMUNOLOGY or VIROLOGY | Investigation | £54 |
| 86606 | Antibody; aspergillus | IMMUNOLOGY or VIROLOGY | Investigation | £38 |
| 86611 | Antibody; bartonella | IMMUNOLOGY or VIROLOGY | Investigation | £60 |
| 86615 | Antibody; bordetella | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86618 | Antibody; borrelia burgdorferi (lyme disease) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86619 | Antibody; borrelia (relapsing fever) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86625 | Antibody; Campylobacter | IMMUNOLOGY or VIROLOGY | Investigation | £42 |
| 86628 | Antibody; candida | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86635 | Antibody; coccidioides (coccidiodal) | IMMUNOLOGY or VIROLOGY | Investigation | £55 |
| 86638 | Antibody; coxiella brunetii (Q fever) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86641 | Antibody; cryptococcus (cryptococcal) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86648 | Antibody; diphtheria | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86651 | Antibody; encephalitis | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86658 | Antibody; enterovirus (eg, coxsackie, echo, polio) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86663 | Antibody; Epstein-Barr virus (EB) (EBV) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86664 | Antibody; Epstein-Barr (EB) virus, nuclear antigen (EBNA) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86665 | Antibody; Epstein-Barr (EB) virus, viral capsid (VCA) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86671 | Antibody; fungus, not elsewhere specified | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86677 | Antibody; helicobacter pylori (h Pylori level) (h Pylori IgG antibody) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86684 | Antibody; hemophilus, haemophilus influenza | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86687 | Antibody; HTLV-I (HTLV I) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86688 | Antibody; HTLV-II (HTLV II) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86689 | Antibody; HTLV or HIV, confirmatory test (Western Blot) | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 86692 | Antibody; hepatitis, delta agent, hepatitis D | IMMUNOLOGY or VIROLOGY | Investigation | £70 |
| 86694 | Antibody; herpes simplex (HSV serology) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86701 | Antibody; HIV-1; HIV antibody detection; HTLV-III, elisa (Formerly code 86690) | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 86702 | Antibody; HIV-2 | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 86703 | Antibody; HIV-1 and HIV-2, single assay | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 86704 | Hepatitis B core antibody (HBcAb); total | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 86705 | Hepatitis B core antibody (HBcAb); IgM antibody | IMMUNOLOGY or VIROLOGY | Investigation | £21 |
| 86706 | Hepatitis B surface antibody (HBsAb) | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 86707 | Hepatitis Be antibody (HBeAb) (HBeAg) | IMMUNOLOGY or VIROLOGY | Investigation | £18 |
| 86708 | Hepatitis A antibody (HAAb) (anti-HAV); total | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 86709 | Hepatitis A antibody (HAAb) (anti-HAV); IgM antibody | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 86710 | Antibody; influenza virus | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86713 | Antibody; legionella | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86735 | Antibody; mumps | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86738 | Antibody; mycoplasma | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86741 | Antibody; neisseria meningitidis (meningococcal conjugate C) | IMMUNOLOGY or VIROLOGY | Investigation | £39 |
| 86747 | Antibody; parvovirus | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86750 | Antibody; plasmodium (malaria) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86756 | Antibody; respiratory syncytial virus (RSV anitbody) (RSV titer) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86757 | Antibody; rickettsia | IMMUNOLOGY or VIROLOGY | Investigation | £41 |
| 86759 | Antibody; rotavirus | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86762 | Antibody; rubella | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 86765 | Antibody; rubeola (measles) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86774 | Antibody; tetanus (PRP-T antibody) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86777 | Antibody; toxoplasma (toxoplasmosis Ab) | IMMUNOLOGY or VIROLOGY | Investigation | £24 |
| 86778 | Antibody; toxoplasma, IgM (toxoplasmosis Ab) | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 86780 | Antibody; treponema pallidum | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86787 | Antibody; varicella zoster virus (VZV) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86790 | Antibody; virus, viral not elsewhere specified | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86793 | Antibody; Yersinia | IMMUNOLOGY or VIROLOGY | Investigation | £47 |
| 86800 | Antibody; thyroglobulin | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86803 | Hepatitis C antibody (HCVab) (anti-HCV) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86804 | Hepatitis C antibody; confirmatory test (eg, immunoblot) | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86807 | Serum screening for cytotoxic percent reactive antibody (PRA); standard method | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86850 | Antibody screen, RBC, antibody to specific drug, each serum technique | IMMUNOLOGY or VIROLOGY | Investigation | £29 |
| 86970 | Pretreatment of RBCs for use in RBC antibody detection, identification and/or compatibility testing; incubation with chemical agents or drugs each | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87267 | Infectious agent antigen detection by immunofluorescent technique; enterovirus, direct fluorescent antibody (formerly code 87199) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87271 | Infectious agent antigen detection by immunofluorescent technique; cytomegalovirus, direct fluorescent antibody (formerly code 87198) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87277 | Legionella | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87280 | Infectious agent antigen detection by immunofluorescent technique; respiratory syncytial virus | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87305 | Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple-step method; Aspergillus | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87324 | Infectious agent antigen detection by enzyme immunoassay technique qualitative or semiquantitative, multiple step method; Clostridium difficile toxin(s) | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 87328 | Cryptosporidium/giardia | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87335 | Escherichia coli 0157 (E coli) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87338 | Infectious agent antigen detection by enzyme immunoassay technique qualitative or semiquantitative, multiple step method; Helicobacter pylori, stool | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87340 | hepatitis B surface antigen (HBsAg) | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 87350 | hepatitis Be antigen (HBeAg) | IMMUNOLOGY or VIROLOGY | Investigation | £18 |
| 87380 | Infectious agent antigen detection by enzyme immunoassay technique qualitative or semiquantitative, multiple step method; hepatitis, delta agent | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 87385 | Histoplasma capsulatum | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87390 | HIV-1 | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 87391 | HIV-2 | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 87400 | Infectious agent antigen detection by enzyme immunoassay technique qualitative or semiquantitative, multiple step method; Influenza, A or B, each | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87427 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87449 | Infectious agent antigen detection by enzyme immunoassay technique qualitative or semiquantitative; multiple step method, not otherwise specified, each organism | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87490 | Chlamydia trachomatis, direct probe technique | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 87804 | Influenza | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87806 | HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 87807 | Respiratory syncytial virus | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87808 | Trichomonas vaginalis | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87809 | Adenovirus | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87810 | Chlamydia trachomatis | IMMUNOLOGY or VIROLOGY | Investigation | £12 |
| 87850 | Neisseria gonorrhoeae | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87880 | Streptococcus, group A | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 87899 | Infectious agent detection by immunoassay with direct optical observation; not otherwise specified | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 88348 | Electron microscopy; diagnostic: For interpretation and report please use code R8348 | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 89060 | Crystal identification by light microscopy with or without polarizing lens analysis, tissue or any body fluid (except urine) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| 91065 | Breath hydrogen test, lactose tolerance test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth or orocecal gastrointestinal transit) | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| T0801 | Molecular Diagnostics: FLT3 / NPMI Mutation detection | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| T1014 | Hemochromatosis Mutation Detection (CY282Y, H63D, S65C), Hereditary , by Polymerase Chain Reaction/Fluorescene Monitoring | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| T1205 | NRAS Mutation detection by Pyrosequencing, N-RAS oncogene, Neuroblastoma RAS Viral Oncogene Homolog | IMMUNOLOGY or VIROLOGY | Investigation | £48 |
| T6711 | Hepatitis A antibody (anti-HAV); IgG antibody (Formerly QuintilesIMS code 86711) | IMMUNOLOGY or VIROLOGY | Investigation | £13 |
| 10022 | Fine needle aspiration; with imaging guidance; include code 76942 or 77012 for imaging | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £673 |
| 11100 | Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £527 |
| 11101 | Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure); each separate/additional lesion (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £527 |
| 11755 | Biopsy of nail unit (eg, plate, bed, matrix hyponychium, proximal and lateral nail folds) (separate procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £527 |
| 17311 | Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation; first stage, up to 5 tissue blocks | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,494 |
| 17312 | Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stains, head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; each additional stage after the first stage, up to 5 tissue blocks | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,494 |
| 17313 | Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,494 |
| 17314 | Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stains, of the trunk, arms, or legs; each additional stage after the first stage, up to 5 tissue blocks | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,494 |
| 17315 | Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stains; each additional block after the first 5 tissue blocks, any stage | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,494 |
| 19081 | Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 19082 | Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 19083 | Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,694 |
| 19084 | Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,694 |
| 19085 | Biopsy, breast, with placement of breast localization device(s) (eg., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,046 |
| 19086 | Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including magentic resonance guidance (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,046 |
| 19100 | Biopsy of breast; percutaneous needle core: Includes anesthesia, Excludes preoperative and postoperative care; without imaging guidance | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 19101 | Biopsy of breast; open, incisional: Includes anesthesia, Excludes preoperative and postoperative care. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 20200 | Biopsy of muscle; superficial | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,000 |
| 20205 | Biopsy of muscle; deep | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,625 |
| 20206 | Biopsy of muscle; percutaneous needle | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £682 |
| 20220 | Biopsy of bone; by trocar or needle: Includes preoperative care (including a medical history and physical examination), anesthesia and typical postoperative care; superficial(eg, ilium, sternum, spinous process, ribs) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,002 |
| 20225 | Biopsy of bone; trocar or needle, deep (eg, vertebral body, femur) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,002 |
| 20245 | Biopsy, bone, open; deep (eg. Humerus, ischium, femur) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,002 |
| 21550 | Biopsy of soft tissue of neck or thorax | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £527 |
| 27330 | Arthrotomy, knee; with synovial biopsy only | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 27331 | Arthrotomy, knee; including joint exploration, biopsy or removal of loose or foreign bodies | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 29900 | Arthroscopy, metacarpophalangeal joint, diagnostic, includes synovial biopsy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 30100 | Biopsy, intranasal: Includes preoperative care (including a medical history and physical examination), anesthesia and typical postoperative care. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 31231 | Nasal, sinus endoscopy, rhinoscopy; diagnostic; unilateral or bilateral | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £658 |
| 31237 | Nasal, sinus endoscopy, rhinoscopy; surgical, with biopsy, polypectomy or debridement (separate procedures) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £801 |
| 31510 | Laryngoscopy, indirect; with biopsy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £615 |
| 31576 | Laryngoscopy, flexible fiberoptic; with biopsy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 31625 | Bronchoscopy, rigid or flexible, with or without flouroscopic guidance, with bronchial or endobronchial biopsy(s), single or multiple sites; diagnostic, with or without cell washing (separate procedure); with anesthesia and typical post-operative care; use in conjunction with code 31620 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,660 |
| 31628 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,660 |
| 31652 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,313 |
| 31653 | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,313 |
| 32096 | Thoracotomy, with diagnostic biopsy(ies) of lung infiltrate(s) (eg, wedge, incisional), unilateral | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32097 | Thoracotomy, with diagnostic biopsy(ies) of lung nodule(s) or mass(es) (eg, wedge, incisional), unilateral | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32098 | Thoracotomy, with biopsy(ies) of pleura | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32405 | Biopsy of lung or mediastinum; percutaneous needle: Includes preoperative care (including a medical history and physical examination), anesthesia and typical postoperative care. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32555 | Thoracentesis, needle or catheter, aspiration of the pleural space; with imaging guidance (formerly Code 32421) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,643 |
| 32557 | Pleural drainage, percutaneous, with insertion of indwelling catheter; with imaging guidance, (formerly Code 32421) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,584 |
| 32604 | Thoracoscopy, diagnostic (separate procedure); pericardial sac, with biopsy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32606 | Thoracoscopy, diagnostic (separate procedure); mediastinal space, with biopsy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32607 | Thoracoscopy, with diagnostic biopsy(ies) of lung infiltrates(s) (eg, wedge, incisional), unilateral (formerly code 32602) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32608 | Thoracoscopy, with diagnostic biopsy(ies) of lung module(s) or mass(es) (eg, wedges, incisional), unilateral (formerly code 32602) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 32609 | Thoracoscopy, with biopsy(ies) of pleura (formerly code 32602) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 36251 | Selective catheter placement (first-order), main renal artery and any accessory renal artery(s) for renal angiography, including arterial puncture and catheter placement(s), fluoroscopy, contrast injection(s), image postprocessing, permanent recording of images, and radiological supervision and interpretation, including pressure gradient measurements when performed, and flush aortogram when performed; unilateral (formerly code 75722) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,860 |
| 36252 | Selective catheter placement (first-order), main renal artery and any accessory renal artery(s) for renal angiography, including arterial puncture and catheter placement(s), fluoroscopy, contrast injection(s), image post processing, permanent recording of images, and radiological supervision and interpretation, including pressure gradient measurements when performed, and flush aortogram when performed; bilateral (formerly code 75722, 75724) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,860 |
| 36253 | Superselective catheter placement (one or more second order or higher renal artery branches) renal artery and any accessory renal artery(s) for renal angiography, including arterial puncture and catheter placement(s), fluoroscopy, contrast injection(s), image pos tprocessing, permanent recording of images, and radiological supervision and interpretation, including pressure gradient measurements when performed, and flush aortogram when performed; unilateral (formerly code 75722, 75724) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,860 |
| 36254 | Superselective catheter placement (one or more second order or higher renal artery branches) renal artery and any accessory renal artery(s) for renal angiography, including arterial puncture and catheter placement(s), fluoroscopy, contrast injection(s), image post processing, permanent recording of images, and radiological supervision and interpretation, including pressure gradient measurements when performed, and flush aortogram when performed; bilateral (formerly code 75722, 75724) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,860 |
| 37200 | Transcatheter biopsy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 37228 | Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty; moderate sedation; please include code 37250 if needed | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37229 | Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with atherectomy, includes angioplasty within the same vessel, when performed; moderate sedation; please include code 37250 if needed | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37230 | Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed; moderate sedation; please include code 37250 if needed | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37231 | Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed; moderate sedation; please include code 37250 if needed | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37233 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with atherectomy, includes angioplasty within the same vessel, when performed (list separately in addition to code for primary procedure); moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37234 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (list separately in addition to code for primary procedure); moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37235 | Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty with the same vessel, when performed (list separately in addition to code for primary procedure); moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37236 | Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; initial artery (Suggested replacement code for 37205) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37237 | Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; each additional artery (list separately in addition to code for primary) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37238 | Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; initial vein (Suggested replacement code for 37205) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37239 | Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; each additional vein (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £6,209 |
| 37252 | Intravascular ultrasound (noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation; initial noncoronary vessel (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £563 |
| 37253 | Intravascular ultrasound (noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation; each additional noncoronary vessel (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £563 |
| 43239 | Upper gastrointestinal endoscopy including esophagus, oesophagus, stomach, and either the duodenum and/or jejunum as appropriate; with biopsy; single or multiple; moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,273 |
| 43242 | Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,236 |
| 43246 | Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with directed placement of percutaneous gastrostomy tube; moderate sedation | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 43254 | Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 43605 | Biopsy of stomach, gastric biopsy; by laparotomy | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 43754 | Gastric intubation and aspiration, diagnostic; single specimen (eg, acid analysis) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £673 |
| 43755 | Gastric intubation and aspiration diagnostic; collection of multiple fractional specimens with gastric stimulation, single or double lumen tube (gastric secretory study) (eg, histamine, insulin, pentagastrin, calcium, secretin), includes drug administration | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £673 |
| 43756 | Duodenal intubation and aspiration, diagnostic, includes image guidance; single specimen (eg. Bile study for crystals or afferent loop culture) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £673 |
| 43757 | Duodenal intubation and aspiration, diagnostic, includes image guidance; collection of multiple fractional specimens with pancreatic or gallbladder stimulation, single or double lumen tube, includes drug administration | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £673 |
| 43775 | Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy) | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,601 |
| 44020 | Enterotomy, small intestine, other than duodenum; for exploration, biopsy(s) or foreign body removal | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 44100 | Biopsy of intestine, colon; by capsule, tube or peroral: Includes preoperative care (including a medical history and physical examination), anesthesia and typical postoperative care. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 44180 | Laparoscopy, surgical, enterolysis | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 44385 | Endoscopic evaluation of small intestinal (abdominal or pelvic) pouch (endoscopy); diagnostic; with or without collection of specimen by brushing or washing; moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,129 |
| 44386 | Endoscopic evaluation of small intestinal (abdominal or pelvic) pouch (endoscopy); with biopsy; single or multiple; moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,273 |
| 44389 | Colonoscopy through stoma (endoscopy); with biopsy; single or multiple; moderate sedation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,273 |
| 45305 | Proctosigmoidoscopy, rigid; with biopsy, single or multiple | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 45330 | Sigmoidoscopy, flexible; diagnostic, with or without collection of specimen(s) by brushing or washing | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 45331 | Sigmoidoscopy, flexible; diagnostic, with biopsy; single or multiple | INTERVENTIONAL DIAGNOSTICS | Investigation | £144 |
| 45333 | Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps | INTERVENTIONAL DIAGNOSTICS | Investigation | £144 |
| 45338 | Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 45346 | Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed) | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,601 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 45388 | Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed); moderate sedation | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,601 |
| 45390 | Colonoscopy, flexible; with endoscopic mucosal resection | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 46600 | Anoscopy; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 46604 | Anoscopy; with dilation (eg, balloon, guide wire, bougie) | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 46606 | Anoscopy; with biopsy, single or multiple | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| 47562 | Laparoscopy, cholecystectomy, excision of gallbladder; surgical | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 47563 | Laparoscopy, surgical; cholecystectomy with cholangiography | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 47564 | Laparoscopy, surgical; cholecystectomy with exploration of common duct | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 47570 | Laparoscopy, surgical; cholecystoenterostomy | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 49320 | Laparoscopy, abdomen, peritoneum, and omentum diagnostic with or without collection of specimen(s) by brushing or washing (separate procedure) | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 49418 | Insertion of tunneled intraperitoneal catheter (eg, dialysis, intraperitoneal chemotherapy instillation, management of ascites), complete procedure, including imaging guidance, catheter placement, contrast injection when performed, and radiological supervision and interpretation, percutaneous | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £881 |
| 51798 | Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £563 |
| 51992 | Laparoscopy, surgical; sling operation for stress incontine (eg, fascia or synthetic) | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 52000 | Cystourethroscopy (separate procedure) | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 52005 | Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service; | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 52224 | Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of lesions | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 52332 | Cystourethroscopy, with insertion of indwelling ureteral stent (e Gibbons or double-J type) | INTERVENTIONAL DIAGNOSTICS | Investigation | £658 |
| 52351 | Cystourethroscopy, with ureteroscopy and/or pyeloscopy; diagnostic | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 52353 | Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lith (ureteral catheterization is included) | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 57452 | Colposcopy (vaginoscopy) | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 57460 | Colposcopy (vaginoscopy); with loop electrode excision procedure of the cervix | INTERVENTIONAL DIAGNOSTICS | Investigation | £1,129 |
| 58555 | Hysteroscopy; diagnostic | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 58670 | Laparoscopy; surgical, with fulguration of oviducts | INTERVENTIONAL DIAGNOSTICS | Investigation | £187 |
| 61140 | Burr hole(s) or trephine; with biopsy of brain or intracranial lesion | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,558 |
| 61750 | Stereotactic biopsy, aspiration, or excision, including burr hole(s) for intracranial lesion; | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £202 |
| 61751 | Stereotactic biopsy, aspiration, or excision, including burr hole(s) for intracranial lesion; with computerized axial tomography and/or magnetic resonance guidance | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £202 |
| 67028 | Intravitreal injection of a pharmacologic agent: includes ophthalmoscopy or ultrasound for needle location, post treatment observation and post injection tonometry; unilateral; for sterile room please add code NP009 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,007 |
| 75989 | Radiological guidance for percutaneous drainage of abscess or specimen collection (ie, fluoroscopy, ultrasound, or computed axial tomography) with possible placement of indwelling catheter: Includes radiological supervision and interpretation | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £359 |
| 76000 | Fluoroscopy; up to one hour physician time (eg, cardiac fluoroscopy) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £345 |
| 77001 | Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or catheter with related venography radiologic supervision and interpretation, and radiographic documentation of final catheter position): Reporting code R7001 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,133 |
| 77002 | Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device): Reporting code R7002. | INTERVENTIONAL DIAGNOSTICS | Investigation | £191 |
| 77011 | Computed tomography guidance for stereotactic localization: Reporting code R7011 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £169 |
| 77012 | Computed tomography guidance for needle placement (eg, biopsy, aspiration, injection, localization device), radiological supervision and interpretation: Reporting code R7012. | INTERVENTIONAL DIAGNOSTICS | Investigation | £405 |
| 77013 | Computed tomography guidance for, and monitoring of, parenchymal tissue ablation: Reporting code R7013 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £169 |
| 77014 | Computed tomography guidance for placement of radiation therapy fields: Reporting code R7014 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £169 |
| 77021 | Magnetic resonance guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation: Reporting code R7021 | INTERVENTIONAL DIAGNOSTICS | Investigation | £404 |
| 77022 | Magnetic resonance guidance for, and monitoring of, parenchymal tissue ablation: Reporting code R7022 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £404 |
| 78647 | Cerebrospinal fluid flow, imaging (not including introduction of material) (CSF), tomographic (SPECT): Reporting code R8647. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £733 |
| 88172 | Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site | INTERVENTIONAL DIAGNOSTICS | Investigation | £136 |
| 88173 | Cytopathology, evaluation of fine needle aspirate; interpretation and report | INTERVENTIONAL DIAGNOSTICS | Investigation | £136 |
| 94806 | Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement): Reporting code R4806 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,067 |
| 95800 | Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time: Reporting code R5800 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,067 |
| 95801 | Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (eg, by airflow or peripheral arterial tone): Reporting code R5801 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £2,067 |
| 0346T | Ultrasound, elastography (List separately in addition to code for primary procedure) | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £138 |
| GSCON | Gastric and colonic motility scintigraphy study including radiopharmaceutical ingestion followed by images between 0 to 24 hours; HIDA-CCK cholescintigraphy; selenium-75 homotaurocholate (SEHCAT); Reporting code RSCON. | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £4,330 |
| T0601 | Biopsy of Bone with ancillary costs including biopsy handling, supplies, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,002 |
| T0602 | Biopsy of Liver with ancillary costs including biopsy handling, ultrasonic guidance, supplies, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0603 | Biopsy, intranasal with ancillary costs including biopsy handling, supplies, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0604 | Bronchoscopy with biopsy with ancillary costs including biopsy handling, supplies, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,728 |
| T0605 | Biopsy of Lung or Mediastinum; percutaneous needle; with ancillary cost including biopsy handling, supplies, ultrasonic guidance, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,154 |
| T0606 | Bone marrow biopsy by trocar needle with ancillary costs including biopsy handling, supplies, coordinator and physician fee, daily facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,002 |
| T0607 | Upper gastrointestinal endoscopy with biopsy with ancillary costs including biopsy handling, supplies, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,273 |
| T0608 | Biopsy of stomach, gastric biopsy by capsule, tube or peroral, with ancillary costs including biopsy handling, supplies, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0609 | Biopsy of stomach by laparotomy with ancillary costs including biopsy handling, supplies, ultrasonic guidance, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0610 | Colonoscopy with specimen collection with ancillary costs including biopsy handling, supplies, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0611 | Renal biopsy by trocar needle with ancillary costs including biopsy handling, supplies, ultrasonic guidance, coordinator and physician fee, overnight facility fee | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0612 | Renal biopsy by surgical exposure, with ancillary costs including biopsy handling, supplies, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0613 | Thyroid biopsy with ancillary costs including biopsy handling, supplies, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0614 | Nerve Biopsy with ancillary costs including biopsy handling, supplies, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0615 | Endomyocardial biopsy, myocardial biopsy with ancillary costs including biopsy handling, supplies, ultrasonic guidance, coordinator and physician fee, overnight facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,154 |
| T0616 | Biopsy of Prostate with ancillary costs, transrectal, including biopsy handling, supplies, ultrasonic needle guidance, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T0617 | Biopsy of Lymph node, superficial including biopsy handling, supplies, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,666 |
| T0618 | Breast Biopsy percutaneous needle, with ancillary costs including biopsy handling, supplies, ultrasonic needle guidance, coordinator and physician fee, day facility | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,085 |
| T1402 | Transjugular liver biopsy including ancillary costs such as facility fee, supplies, biopsy handling, staff time, anesthesia. This complete code also includes CPT codes 37200,36011 (Selective catheter placement), 75970 (radiological supervision ,without interpretation: Reporting code R5970), 76937 (Ultrasound guidance, without interpretation: Reporting code R6937) If Hepatic venography is required please include code 75889 | INTERVENTIONAL DIAGNOSTICS | Intervention includes Investigation (where applicable) | £1,149 |
| 80150 | Amikacin | MICROBIOLOGY | Investigation | £49 |
| 80156 | Carbamazepine; total | MICROBIOLOGY | Investigation | £35 |
| 80158 | Cyclosporine (CyA) (CsA) | MICROBIOLOGY | Investigation | £35 |
| 80162 | Digoxin | MICROBIOLOGY | Investigation | £35 |
| 80164 | Dipropylacetic acid (valproic acid) | MICROBIOLOGY | Investigation | £35 |
| 80168 | Ethosuximide | MICROBIOLOGY | Investigation | £47 |
| 80170 | Gentamicin | MICROBIOLOGY | Investigation | £35 |
| 80173 | Haloperidol | MICROBIOLOGY | Investigation | £35 |
| 80176 | Lidocaine | MICROBIOLOGY | Investigation | £35 |
| 80178 | Lithium | MICROBIOLOGY | Investigation | £35 |
| 80184 | Phenobarbital | MICROBIOLOGY | Investigation | £35 |
| 80185 | Phenytoin; total | MICROBIOLOGY | Investigation | £35 |
| 80186 | Phenytoin; total; free | MICROBIOLOGY | Investigation | £35 |
| 80188 | Primidone | MICROBIOLOGY | Investigation | £35 |
| 80190 | Procainamide | MICROBIOLOGY | Investigation | £35 |
| 80194 | Quinidine | MICROBIOLOGY | Investigation | £35 |
| 80197 | Tacrolimus; whole blood by IMx analysis | MICROBIOLOGY | Investigation | £35 |
| 80198 | Theophylline | MICROBIOLOGY | Investigation | £35 |
| 80200 | Tobramycin | MICROBIOLOGY | Investigation | £35 |
| 80201 | Topiramate | MICROBIOLOGY | Investigation | £35 |
| 80202 | Vancomycin | MICROBIOLOGY | Investigation | £35 |
| 80299 | Quantitation of drug, not elsewhere specified | MICROBIOLOGY | Investigation | £35 |
| 80305 | Drug test(s), presumptive, any number of drug classes, direct optical observation only includes sample validation when performed | MICROBIOLOGY | Investigation | £35 |
| 80306 | Drug test(s), presumptive, any number of drug classes, instrument assisted direct optical observation, includes sample validation when performed | MICROBIOLOGY | Investigation | £35 |
| 80307 | Drug test(s), presumptive, instrument chemistry analyzers chromatography, and mass spectrometry includes sample validation when performed, per date of service | MICROBIOLOGY | Investigation | £35 |
| 80320 | Alcohols | MICROBIOLOGY | Investigation | £35 |
| 80321 | Alcohol biomarkers; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80322 | Alcohol biomarkers; 3 or more | MICROBIOLOGY | Investigation | £35 |
| 80323 | Alkaloids, not otherwise specified | MICROBIOLOGY | Investigation | £35 |
| 80324 | Amphetamines; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80325 | Amphetamines; 3 or 4 | MICROBIOLOGY | Investigation | £35 |
| 80326 | Amphetamines; 5 or more | MICROBIOLOGY | Investigation | £35 |
| 80327 | Anabolic steroids; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80328 | Anabolic steroids; 3 or more | MICROBIOLOGY | Investigation | £35 |
| 80329 | Analgesics, non-opioid; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80330 | Analgesics, non-opioid; 3-5 | MICROBIOLOGY | Investigation | £35 |
| 80331 | Analgesics, non-opioid; 6 or more | MICROBIOLOGY | Investigation | £35 |
| 80335 | Antidepressants, tricyclic and other cyclicals; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80336 | Antidepressants, tricyclic and other cyclicals; 3-5 | MICROBIOLOGY | Investigation | £35 |
| 80337 | Antidepressants, tricyclic and other cyclicals; 6 or more | MICROBIOLOGY | Investigation | £35 |
| 80339 | Antiepileptics, not otherwise specified; 1-3 | MICROBIOLOGY | Investigation | £35 |
| 80340 | Antiepileptics, not otherwise specified; 4-6 | MICROBIOLOGY | Investigation | £35 |
| 80341 | Antiepileptics, not otherwise specified; 7 or more | MICROBIOLOGY | Investigation | £35 |
| 80342 | Antipsychotics, not otherwise specified; 1-3 | MICROBIOLOGY | Investigation | £35 |
| 80343 | Antipsychotics, not otherwise specified; 4-6 | MICROBIOLOGY | Investigation | £35 |
| 80344 | Antipsychotics, not otherwise specified; 7 or more | MICROBIOLOGY | Investigation | £35 |
| 80345 | Barbiturates | MICROBIOLOGY | Investigation | £35 |
| 80346 | Benzodiazepines; 0-12 | MICROBIOLOGY | Investigation | £35 |
| 80347 | Benzodiazepines; 13 or more | MICROBIOLOGY | Investigation | £35 |
| 80353 | Cocaine | MICROBIOLOGY | Investigation | £35 |
| 80358 | Methadone | MICROBIOLOGY | Investigation | £35 |
| 80361 | Opiates, 1 or more | MICROBIOLOGY | Investigation | £35 |
| 80362 | Opioids and opiate analogs; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80363 | Opioids and opiate analogs; 3 or 4 | MICROBIOLOGY | Investigation | £35 |
| 80364 | Opiods and opiate analogs; 5 or more | MICROBIOLOGY | Investigation | £35 |
| 80368 | Sedative hypnotics (non-benzodiazepines) | MICROBIOLOGY | Investigation | £35 |
| 80369 | Skeletal muscle relaxants; 1 or 2 | MICROBIOLOGY | Investigation | £35 |
| 80370 | Skeletal muscle relaxants; 3 or more | MICROBIOLOGY | Investigation | £35 |
| 86060 | Antistreptolysin 0 (ASO) (ASLO); titer | MICROBIOLOGY | Investigation | £13 |
| 86480 | Tuberculosis test, cell mediated immunity measurement of gamma interferon antigen response (e.g. QFTB: QuantiFeron-TB Gold test) | MICROBIOLOGY | Investigation | £42 |
| 86481 | Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | MICROBIOLOGY | Investigation | £18 |
| 86580 | Skin test, tuberculosis (TB); intradermal, Mantoux screening test, Tuberculin Sensitivity Test, Pirquet test, PPD test for Purified Protein Derivative | MICROBIOLOGY | Investigation | £18 |
| 87040 | Culture, bacterial; blood, serum, with isolation and presumptive identification of isolates | MICROBIOLOGY | Investigation | £18 |
| 87045 | Culture, bacterial; feces, fecal, stool, with isolation and presumptive identification of isolates | MICROBIOLOGY | Investigation | £18 |
| 87046 | Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate | MICROBIOLOGY | Investigation | £18 |
| 87070 | Culture, bacterial; any other source except urine, blood, serum, stool or feces, with isolation and presumptive identification of isolates | MICROBIOLOGY | Investigation | £12 |
| 87071 | Culture, bacterial; quantitative, aerobic with isolation an identification of isolates, any source except urine, blood or stool | MICROBIOLOGY | Investigation | £12 |
| 87075 | Culture, bacterial; any anaerobic source, except blood, presumptive identification of isolates | MICROBIOLOGY | Investigation | £18 |
| 87076 | Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolatev | MICROBIOLOGY | Investigation | £18 |
| 87077 | Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate | MICROBIOLOGY | Investigation | £18 |
| 87081 | Culture, pathogenic organisms, presumptive, screening only; including nasal swab | MICROBIOLOGY | Investigation | £18 |
| 87086 | Culture, bacterial; urine, quantitative colony count | MICROBIOLOGY | Investigation | £12 |
| 87088 | Culture, bacterial; urine, with isolation and presumptive identification of isolates | MICROBIOLOGY | Investigation | £12 |
| 87101 | Culture, fungi, fungal (mold or yeast) isolation; skin, hair or nail, with presumptive identification of isolates | MICROBIOLOGY | Investigation | £18 |
| 87102 | Culture, fungi, fungal (mold or yeast) isolation; other source (except blood), with presumptive identification of isolates | MICROBIOLOGY | Investigation | £18 |
| 87103 | Culture, fungi, fungal (mold or yeast) isolation; blood, serum, with presumptive identification of isolates | MICROBIOLOGY | Investigation | £18 |
| 87106 | Culture, fungi, fungal (mold or yeast); definitive identification | MICROBIOLOGY | Investigation | £18 |
| 87109 | Culture, mycoplasma; any source | MICROBIOLOGY | Investigation | £18 |
| 87110 | Culture, chlamydia; any source | MICROBIOLOGY | Investigation | £33 |
| 87116 | Culture, tubercle or other acid-fast bacilli (eg, TB, AFB); any source | MICROBIOLOGY | Investigation | £18 |
| 87140 | Culture, typing; immunofluorescent method, each antiserum | MICROBIOLOGY | Investigation | £18 |
| 87143 | Culture, typing; gas liquid chromatography (GLC) or high pressure liquid chromatography (HPLC) method | MICROBIOLOGY | Investigation | £18 |
| 87147 | Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum | MICROBIOLOGY | Investigation | £18 |
| 87230 | Toxin or antitoxin assay, tissue culture (eg, Clostridium difficile toxin (C-diff)) | MICROBIOLOGY | Investigation | £13 |
| 88230 | Tissue culture for non-neoplastic disorders; lymphocyte | MICROBIOLOGY | Investigation | £18 |
| 88237 | Tissue culture for neoplastic disorders; bone marrow, blood cells | MICROBIOLOGY | Investigation | £18 |
| 88239 | Tissue culture for neoplastic disorders; solid tumor | MICROBIOLOGY | Investigation | £18 |
| 89220 | Sputum, obtaining specimen, aerosol induced technique (formerly code 89350) | MICROBIOLOGY | Investigation | £18 |
| 94640 | Nonpressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (e.g. aerosol generator, nebulizer) | MICROBIOLOGY | Investigation | £18 |
| T0703 | Viral Serology: Hepatitis B, HBsAG, Hepatitis C,HCV, Human immunodeficiency virus, HIV | MICROBIOLOGY | Investigation | £13 |
| T0717 | Cytogenetics Analysis including tissue culture; molecular cytogenetics with karyotyping and banding | MICROBIOLOGY | Investigation | £18 |
| T2964 | Glucosaminoglycans (GAG), N-acetyl beta-glucosaminidase (NAG); urine (Formerly QuintilesIMS code 82964) | MICROBIOLOGY | Investigation | £12 |
| T6585 | Skin test check, tuberculosis (TB); tine test check (Formerly QuintilesIMS code 86585) | MICROBIOLOGY | Investigation | £18 |
| T7072 | Culture, bacterial; throat or nose, aerobic with definitive identification (Formerly QuintilesIMS code 87072) | MICROBIOLOGY | Investigation | £18 |
| 76073 | DEXA Per site | NUCLEAR MEDICINE | Investigation | £88 |
| 78013 | Thyroid imaging Complex | NUCLEAR MEDICINE | Investigation | £537 |
| 78195 | Lymphatics and lymph nodes imaging Any area | NUCLEAR MEDICINE | Investigation | £1,092 |
| 78205 | SPECT Any area | NUCLEAR MEDICINE | Investigation | £354 |
| 78227 | Hepatobiliary system imaging, including gallbladder when present; with pharmacologic intervention, including quantitative measurement(s) when performed. Reporting code R8227 Any area | NUCLEAR MEDICINE | Investigation | £832 |
| 78231 | Salivary gland imaging 1 or more sites | NUCLEAR MEDICINE | Investigation | £515 |
| 78350 | Bone Scan 1 Site | NUCLEAR MEDICINE | Investigation | £213 |
| 78351 | Bone Scan 5 sites/more/whole body | NUCLEAR MEDICINE | Investigation | £317 |
| 78451 | SPECT 5 sites/more/whole body | NUCLEAR MEDICINE | Investigation | £475 |
| 78452 | SPECT any area | NUCLEAR MEDICINE | Investigation | £354 |
| 78608 | PET Scan (CT/MRI) Any area | NUCLEAR MEDICINE | Investigation | £1,542 |
| 78803 | SPECT any area | NUCLEAR MEDICINE | Investigation | £354 |
| 78815 | PET Scan (CT/MRI) Partial body | NUCLEAR MEDICINE | Investigation | £1,542 |
| 92920 | PET Scan (CT/MRI) Whole body | NUCLEAR MEDICINE | Investigation | £1,595 |
| 92921 | Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery. (formerly codes 92980, 92981, 92984, 92995, 92996) | NUCLEAR MEDICINE | Investigation | £4,794 |
| NIHR_INV_053 | Brain Imaging (Choline) for Tumour | NUCLEAR MEDICINE | Investigation | £847 |
| NIHR_INV_054 | Brain Imaging (Thallium) for tumour | NUCLEAR MEDICINE | Investigation | £332 |
| NIHR_INV_056 | DATScan Any area | NUCLEAR MEDICINE | Investigation | £309 |
| NIHR_INV_057 | DMSA Renal | NUCLEAR MEDICINE | Investigation | £483 |
| NIHR_INV_059 | EDTA Renal Clearance (GFR) Any area | NUCLEAR MEDICINE | Investigation | £3,803 |
| NIHR_INV_060 | I131 Therapy Ca thyroid | NUCLEAR MEDICINE | Investigation | £423 |
| NIHR_INV_061 | I131 Therapy Thyrotoxicosis IP | NUCLEAR MEDICINE | Investigation | £1,029 |
| NIHR_INV_062 | I131 Therapy Thyrotoxicosis OP | NUCLEAR MEDICINE | Investigation | £873 |
| NIHR_INV_063 | Intestinal absorption (75-Se) Any area | NUCLEAR MEDICINE | Investigation | £370 |
| NIHR_INV_064 | Lacrimal Scan (Dacroscintigraphy) Any area | NUCLEAR MEDICINE | Investigation | £625 |
| NIHR_INV_065 | Lymphatics and lymph nodes imaging Any area | NUCLEAR MEDICINE | Investigation | £1,092 |
| NIHR_INV_066 | MAG3 Dynamic Renal Scan | NUCLEAR MEDICINE | Investigation | £532 |
| NIHR_INV_067 | MAG3 Dynamic Renal Scan + Bladder Emptying | NUCLEAR MEDICINE | Investigation | £1,506 |
| NIHR_INV_068 | MAG3 Dynamic Renal Scan With Captopril | NUCLEAR MEDICINE | Investigation | £1,200 |
| NIHR_INV_069 | Meckels Scan Complex | NUCLEAR MEDICINE | Investigation | £336 |
| NIHR_INV_070 | MIBG Imaging Any area | NUCLEAR MEDICINE | Investigation | £2,095 |
| T0718 | DEXA Per site | NUCLEAR MEDICINE | Investigation | £88 |
| T6072 | DEXA Per site | NUCLEAR MEDICINE | Investigation | £88 |
| 92235 | Ophthalmic imaging: Fluorescein angiography (per eye) | OPTHALMOLOGY | Investigation | £133 |
| 92240 | Ophthalmic imaging: Indocyanine-green (ICG) angiography | OPTHALMOLOGY | Investigation | £166 |
| 92275 | Ocular electrophysiology: Electroretinography (ERG) | OPTHALMOLOGY | Investigation | £295 |
| 92285 | Ophthalmic imaging: External ocular photography (eg, close-up photography, slit lamp photography, goniophotography, stereo-photography) | OPTHALMOLOGY | Investigation | £44 |
| 92287 | Ophthalmic imaging: Anterior segment fluorescein angiography or other specialised imaging | OPTHALMOLOGY | Investigation | £166 |
| 92541 | Ophthalmic examination: Spontaneous nystagmus test, including gaze and fixation nystagmus; with recording | OPTHALMOLOGY | Investigation | £177 |
| 92542 | Ophthalmic examination: Positional nystagmus test, minimum of 4 positions, with recording | OPTHALMOLOGY | Investigation | £177 |
| 92545 | Ophthalmic examination: Oscillating tracking test, with recording | OPTHALMOLOGY | Investigation | £177 |
| NIHR_INV_071 | Ophthalmology clinics | OPTHALMOLOGY | Investigation | £156 |
| NIHR_INV_072 | Medical / Ophthalmic history | OPTHALMOLOGY | Investigation | £59 |
| NIHR_INV_073 | Visual Acuity Testing: Best-corrected distance visual acuity, either or both eyes (Add refraction if needed) | OPTHALMOLOGY | Investigation | £59 |
| NIHR_INV_074 | Visual Acuity Testing: Contrast sensitivity, either or both eyes (Add refraction if needed) | OPTHALMOLOGY | Investigation | £99 |
| NIHR_INV_075 | Visual Acuity Testing: Low luminance acuity, either or both eyes (Add refraction if needed) | OPTHALMOLOGY | Investigation | £59 |
| NIHR_INV_076 | Ophthalmic examination: Posterior segment only (Indirect ophthalmoscopy) per eye | OPTHALMOLOGY | Investigation | £44 |
| NIHR_INV_077 | Ophthalmic examination: Anterior and posterior segment examination | OPTHALMOLOGY | Investigation | £93 |
| NIHR_INV_078 | Ophthalmic examination: Intra-ocular pressure (per eye) | OPTHALMOLOGY | Investigation | £21 |
| NIHR_INV_079 | Ophthalmic imaging: Autofluorescence Imaging | OPTHALMOLOGY | Investigation | £138 |
| NIHR_INV_080 | Ophthalmic imaging: Adaptive Optics Imaging | OPTHALMOLOGY | Investigation | £104 |
| NIHR_INV_081 | Visual field testing: Micro-perimetry | OPTHALMOLOGY | Investigation | £274 |
| NIHR_INV_083 | Ophthalmic imaging: Fundus photography of disc / macula, incl. stereo photography | OPTHALMOLOGY | Investigation | £70 |
| NIHR_INV_097 | Visual Acuity Testing: Refraction for distance and near | OPTHALMOLOGY | £50 | |
| NIHR_INV_099 | Visual acuity testing: Near visual acuity and reading speed, either or both eyes (Add refraction if needed) | OPTHALMOLOGY | £59 | |
| NIHR_INV_100 | Visual field testing: Peripheral visual field testing (Goldmann visual fields) | OPTHALMOLOGY | £100 | |
| NIHR_INV_101 | Visual field testing: Preferential Hyperacuity Perimetry | OPTHALMOLOGY | £149 | |
| NIHR_INV_102 | Ophthalmic examination: Orthoptic assessment | OPTHALMOLOGY | £85 | |
| NIHR_INV_103 | Ophthalmic examination: Pachymetry | OPTHALMOLOGY | £32 | |
| NIHR_INV_105 | Ophthalmic imaging: OCT-angiography | OPTHALMOLOGY | £128 | |
| NIHR_INV_106 | Ophthalmic imaging: Ultra-widefield fundus photography (incl 7 field imaging) | OPTHALMOLOGY | £128 | |
| NIHR_INV_107 | Ophthalmic imaging: Ultra-widefeld fluorescein angiography | OPTHALMOLOGY | £212 | |
| NIHR_INV_108 | Ophthalmic imaging: Ultra-widefield autofluorescence Imaging | OPTHALMOLOGY | £102 | |
| NIHR_INV_109 | Ophthalmic imaging: Corneal topography | OPTHALMOLOGY | £112 | |
| NIHR_INV_110 | Ophthalmic imaging: Specular microscopy | OPTHALMOLOGY | £92 | |
| NIHR_INV_111 | Ocular electrophysiology: Electroretinography (ERG) and Visual evoked potential (VEP) | OPTHALMOLOGY | £424 | |
| NIHR_INV_112 | Intra-vitreal injection | OPTHALMOLOGY | £100 | |
| T2282 | Ophthalmic examination: Anterior segment only (Slit-lamp examination) Either or both eyes | OPTHALMOLOGY | Investigation | £49 |
| 37609 | Ligation or biopsy, temporal artery | PATHOLOGY | Investigation | £144 |
| 38221 | Bone marrow biopsy; by trocar or needle | PATHOLOGY | Investigation | £58 |
| 38500 | Biopsy or excision of lymph node(s); open: | PATHOLOGY | Investigation | £723 |
| 38505 | Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary) | PATHOLOGY | Investigation | £723 |
| 38510 | Biopsy or excision of lymph node(s); open, deep cervical node(s) | PATHOLOGY | Investigation | £723 |
| 38525 | Biopsy or excision of lymph node(s); open, deep axillary node(s) | PATHOLOGY | Investigation | £723 |
| 38530 | Biopsy or excision of lymph node(s); open, internal mammary node(s) | PATHOLOGY | Investigation | £723 |
| 40490 | Biopsy of lip | PATHOLOGY | Investigation | £56 |
| 40808 | Biopsy, vestibule of mouth: Includes preoperative care (including a medical history and physical examination), anesthesia and typical postoperative care. | PATHOLOGY | Investigation | £56 |
| 41100 | Biopsy of tongue; anterior two-thirds | PATHOLOGY | Investigation | £56 |
| 41108 | Biopsy of floor of mouth | PATHOLOGY | Investigation | £56 |
| 42400 | Biopsy of salivary gland; needle | PATHOLOGY | Investigation | £56 |
| 42405 | Biopsy of salivary gland; incisional | PATHOLOGY | Investigation | £56 |
| 45100 | Rectal biopsy, biopsy of anorectal wall; anal approach | PATHOLOGY | Investigation | £144 |
| 47000 | Biopsy of liver; percutaneous needle: Includes anesthesia, Excludes preoperative and postoperative care. | PATHOLOGY | Investigation | £144 |
| 47001 | Biopsy of liver, needle; when done for indicated purpose at time of other major procedure (List separately in addition to code for primary procedure) | PATHOLOGY | Investigation | £144 |
| 48102 | Biopsy of pancreas; percutaneous needle | PATHOLOGY | Investigation | £144 |
| 49180 | Biopsy of abdomen, abdominal or retroperitoneal mass; percutaneous needle | PATHOLOGY | Investigation | £144 |
| 49321 | Laparoscopy; surgical, with biopsy; single or multiple | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 50200 | Renal biopsy; by trocar or needle; moderate sedation | PATHOLOGY | Investigation | £144 |
| 50205 | Renal biopsy; by surgical exposure of kidney: Includes anesthesia, Excludes preoperative and postoperative care. | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 52204 | Cystourethroscopy, cystoscopy; with biopsy of bladder | PATHOLOGY | Intervention includes Investigation (where applicable) | £144 |
| 54500 | Biopsy of testis, testicle; needle (separate procedure) | PATHOLOGY | Investigation | £144 |
| 54505 | Biopsy of testis, testical; incisional (separate procedure) | PATHOLOGY | Investigation | £144 |
| 55700 | Biopsy of prostate (TURP); by needle or punch: Includes preoperative care, anesthesia and typical postoperative care; single or multiple, any approach | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 55705 | Biopsy of prostate; incisional | PATHOLOGY | Investigation | £144 |
| 57100 | Biopsy of vaginal mucosa; simple | PATHOLOGY | Investigation | £144 |
| 57105 | Biopsy of vaginal mucosa; extensive, requiring suture (including cysts) | PATHOLOGY | Investigation | £144 |
| 57454 | Colposcopy (vaginoscopy); with biopsy(s) of the cervix and/or endocervical curettage | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 57500 | Biopsy, cervical, cervix uteri, single or multiple, or local excision of lesion: Includes anesthesia, Excludes preoperative and postoperative care; with or without fulguration | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 58100 | Endometrial biopsy, uterine biopsy: Includes anesthesia, Excludes preoperative and postoperative care; without cervical dilation, any method | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 58558 | Hysteroscopy; surgical, with biopsy of endometrium and/or polypectomy | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 60100 | Biopsy of thyroid; percutaneous core needle: Includes anesthesia, Excludes preoperative and postoperative care. | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 64795 | Biopsy of nerve: Includes preoperative care (including a medical history and physical examination), anesthesia and typical postoperative care. | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| 67346 | Biopsy of extraocular muscle; for ultrasound guidance please add code 76942 | PATHOLOGY | Investigation | £213 |
| 68100 | Biopsy of conjunctiva | PATHOLOGY | Investigation | £56 |
| 75970 | Transcatheter biopsy, radiological supervision and interpretation: Reporting code R5970 | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,625 |
| 76948 | Ultrasonic guidance for aspiration of ova (ultrasound) (uls): Includes imaging supervision and interpretation; Reporting code R6948. | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,007 |
| 80048 | Basic metabolic panel chemistry: Includes Calcium (82310) Carbon dioxide (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520) | PATHOLOGY | Investigation | £23 |
| 80050 | General health panel | PATHOLOGY | Investigation | £23 |
| 80051 | Electrolyte panel: Includes Carbon dioxide (82374) Chloride (82435) Potassium (84132) Sodium (84295) | PATHOLOGY | Investigation | £23 |
| 80053 | Comprehensive metabolic panel; Includes Albumin, Bilirubin, Calcium, Carbon Dioxide (bicarbonate), Chloride, Creatinine, Glucose, Phosphatase, alkaline, Potassium, Protein, Sodium, Transferase, alanine amino (ALT) (SGPT), aspartate amino (AST) (SGOT), Urea Nitrogen (BUN) | PATHOLOGY | Investigation | £23 |
| 80061 | Lipid Panel I: Includes Total Cholesterol (82465) Lipoprotein, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478) | PATHOLOGY | Investigation | £23 |
| 80069 | Renal function panel: Includes Albumin, Calcium, Carbon dioxide (bicarbonate), Chloride, Creatinine, Glucose, Phosphorus inorganic (phosphate), Potassium, Sodium, Urea nitrogen (BUN) | PATHOLOGY | Investigation | £23 |
| 80074 | Acute hepatitis panel: Includes Hepatitis A antibody (HAAb) IgM antibody, Hepatitis B core antibody (HbcAb) IgM antibody, Hepatitis B surface antigen (HbsAg), Hepatitis C antibody | PATHOLOGY | Investigation | £23 |
| 80076 | Hepatic function panel Liver Function Test: Includes Albumin, Bilirubin, Phosphatase, alkaline Protein, Transferase, alanine amino (ALT) (SGPT), aspartate amino (AST) (SGOT) | PATHOLOGY | Investigation | £23 |
| 80412 | Corticotropic releasing hormone (CRH) stimulation panel: Includes Cortisol (82533) Adrenocorticotropic hormone (ACTH) (82024) | PATHOLOGY | Investigation | £23 |
| 80426 | Gonadotropin releasing hormone stimulation panel (GnRH test): Includes Follicle stimulating hormone (FSH) (83001) Luteinizing hormone (LH) (83002) | PATHOLOGY | Investigation | £23 |
| 80601 | QuintilesIMS code:Two-dimensional gel electrophoresis, staining, digitizing and quantification of known protein | PATHOLOGY | Investigation | £17 |
| 81000 | Urinalysis, by dip stick or tablet reagent for bilirubin, glucose hemoglobin, ketones, leukocytes, nitrite, specific gravity, urobilinogen (urine analysis) (UA); with microscopy, non-automated | PATHOLOGY | Investigation | £19 |
| 81001 | Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | PATHOLOGY | Investigation | £19 |
| 81002 | Urinalysis, by dip stick or tablet reagent for bilirubin, glucose hemoglobin, ketones, leukocytes, nitrite gravity, urobilinogen (urine analysis) (UA); without microscopy, non-automated | PATHOLOGY | Investigation | £19 |
| 81005 | Urinalysis (urine analysis) (UA); qualitative or semiquantitative, except immunoassays | PATHOLOGY | Investigation | £19 |
| 81007 | Urinalysis (urine analysis) (UA); bacteriuria screen, except by culture or dipstick | PATHOLOGY | Investigation | £19 |
| 81015 | Urinalysis (urine analysis) (UA); microscopic only | PATHOLOGY | Investigation | £19 |
| 81025 | Urine pregnancy test; by visual color comparison methods | PATHOLOGY | Investigation | £10 |
| 81240 | F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant | PATHOLOGY | Investigation | £40 |
| 81245 | FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis, internal tandem duplication (ITD) variants (ie, exons 14, 15) | PATHOLOGY | Investigation | £10 |
| 81250 | G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, Type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X) | PATHOLOGY | Investigation | £6 |
| 81252 | GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence | PATHOLOGY | Investigation | £126 |
| 81253 | GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants | PATHOLOGY | Investigation | £17 |
| 81254 | GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13S1854)]) | PATHOLOGY | Investigation | £17 |
| 81260 | IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507 6T>C, R696P) | PATHOLOGY | Investigation | £10 |
| 81270 | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant | PATHOLOGY | Investigation | £10 |
| 81287 | MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme), methylation analysis | PATHOLOGY | Investigation | £166 |
| 81403 | Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis or mutation scanning or duplication/deletion variants of 2-5 exons) | PATHOLOGY | Investigation | £257 |
| 81404 | Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons) | PATHOLOGY | Investigation | £166 |
| 81405 | Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis) | PATHOLOGY | Investigation | £275 |
| 81406 | Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis or duplication/deletion variants of 26-50 exons) | PATHOLOGY | Investigation | £275 |
| 81407 | Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) | PATHOLOGY | Investigation | £166 |
| 81408 | Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) | PATHOLOGY | Investigation | £275 |
| 81445 | Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes interrogation for sequence variants and copy number variants or rearrangements, if performed | PATHOLOGY | Investigation | £166 |
| 81528 | Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool | PATHOLOGY | Investigation | £166 |
| 82013 | Acetylcholinesterase (Rbc) (AChE) | PATHOLOGY | Investigation | £18 |
| 82150 | Amylase | PATHOLOGY | Investigation | £10 |
| 82232 | Beta 2 microglobulin, Beta-2 microglobulin, Alpha 1 microglobulin, Alpha-1 microglobulin; blood, serum, urine | PATHOLOGY | Investigation | £17 |
| 82247 | Bilirubin; total | PATHOLOGY | Investigation | £13 |
| 82248 | Bilirubin; direct | PATHOLOGY | Investigation | £13 |
| 82373 | Carbohydrate deficient transferrin; CDG transferrin isoelectric focusing | PATHOLOGY | Investigation | £17 |
| 82374 | Carbon dioxide (bicarbonate) (HCO3) | PATHOLOGY | Investigation | £13 |
| 82378 | Carcinoembryonic antigen (CEA) | PATHOLOGY | Investigation | £13 |
| 82435 | Chloride, blood | PATHOLOGY | Investigation | £10 |
| 82436 | Chloride; urine | PATHOLOGY | Investigation | £10 |
| 82438 | Chloride; other source | PATHOLOGY | Investigation | £10 |
| 82465 | Cholesterol; total, serum or whole blood | PATHOLOGY | Investigation | £13 |
| 82550 | Creatine kinase (CK) (CPK); total | PATHOLOGY | Investigation | £10 |
| 82552 | Creatine kinase (CK) (CPK); isoenzymes | PATHOLOGY | Investigation | £10 |
| 82553 | Creatine kinase (CK) (CPK) (CK-MB); MB fraction only | PATHOLOGY | Investigation | £10 |
| 82554 | Creatine kinase (CK) (CPK); isoforms | PATHOLOGY | Investigation | £10 |
| 82575 | Creatinine clearance; urine, blood, serum | PATHOLOGY | Investigation | £13 |
| 82585 | Cryofibrinogen | PATHOLOGY | Investigation | £8 |
| 82670 | Estradiol, oestradiol (Es-1) (Es-2) (E2); blood, serum | PATHOLOGY | Investigation | £15 |
| 82715 | Fat differential, feces, fecal, stool | PATHOLOGY | Investigation | £8 |
| 82759 | Galactokinase, RBC | PATHOLOGY | Investigation | £10 |
| 82784 | Gammaglobulin; IgA, IgD, IgG, IgM each | PATHOLOGY | Investigation | £17 |
| 82787 | Gammaglobulin; immunoglobulin subclasses, (IgG1, 2, 3 and 4), quantitative immunoglobulin, each | PATHOLOGY | Investigation | £17 |
| 82945 | Glucose; body fluid, other than blood, serum | PATHOLOGY | Investigation | £6 |
| 82947 | Glucose; blood, serum (except reagent strip); quantitative | PATHOLOGY | Investigation | £6 |
| 82948 | Glucose; blood, serum, reagent strip, finger stick test | PATHOLOGY | Investigation | £6 |
| 82950 | Glucose; post glucose dose (includes glucose) | PATHOLOGY | Investigation | £6 |
| 82951 | Glucose tolerance test (GTT) (OGTT); Includes glucose dose, fasting glucose and 3 post dose glucose specimens | PATHOLOGY | Investigation | £6 |
| 82952 | Glucose tolerance test (GTT); each additional beyond three specimens | PATHOLOGY | Investigation | £6 |
| 82955 | Glucose-6-phosphate dehydrogenase (G6PD) (G-6-PD); quantitative; method by methemoglobin reduction (Brewer's test), modified Bishop (ultraviolet), dye reduction, or ascorbic or fluorescent spot test | PATHOLOGY | Investigation | £6 |
| 82962 | Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | PATHOLOGY | Investigation | £6 |
| 83001 | Gonadotropin; follicle stimulating hormone (FSH) | PATHOLOGY | Investigation | £17 |
| 83002 | Gonadotropin; luteinizing hormone (LH) | PATHOLOGY | Investigation | £13 |
| 83003 | Human growth hormone (HGH) (somatotropin) | PATHOLOGY | Investigation | £13 |
| 83020 | Hemoglobin fractionation and quantitation; electrophoresis (eg, A2, S C, and/or F) | PATHOLOGY | Investigation | £17 |
| 83498 | Hydroxyprogesterone, 17-d (17-OH Progesterone) | PATHOLOGY | Investigation | £19 |
| 83499 | Hydroxyprogesterone, 20- | PATHOLOGY | Investigation | £17 |
| 83540 | Iron (Fe) | PATHOLOGY | Investigation | £10 |
| 83550 | Iron binding capacity (IBC) (TIBC) | PATHOLOGY | Investigation | £8 |
| 83701 | Lipoprotein, blood; electrophoretic seperation and quantitation, high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed | PATHOLOGY | Investigation | £17 |
| 83718 | Lipoprotein, direct measurement; high density cholesterol (HDL) | PATHOLOGY | Investigation | £13 |
| 83719 | Lipoprotein, direct measurement; very low density cholesterol (VLDL) | PATHOLOGY | Investigation | £13 |
| 83721 | Lipoprotein, direct measurement; low density cholesterol (LDL) | PATHOLOGY | Investigation | £13 |
| 83735 | Magnesium (Mg) | PATHOLOGY | Investigation | £10 |
| 83873 | Myelin basic protein, cerebrospinal fluid (CSF) | PATHOLOGY | Investigation | £214 |
| 83880 | Natriuretic peptide, brain nucleic peptide (BNP), substance P; NT Pro BNP | PATHOLOGY | Investigation | £32 |
| 83930 | Osmolality (Osmolarity); blood, serum | PATHOLOGY | Investigation | £10 |
| 83935 | Osmolality (Osmolarity); urine | PATHOLOGY | Investigation | £10 |
| 83970 | Parathormone (parathyroid hormone) (PTH) | PATHOLOGY | Investigation | £33 |
| 84144 | Progesterone | PATHOLOGY | Investigation | £17 |
| 84146 | Prolactin (PRL) | PATHOLOGY | Investigation | £17 |
| 84152 | Prostate specific antigen (PSA); complexed (direct measurement) | PATHOLOGY | Investigation | £17 |
| 84153 | Prostate specific antigen (PSA); total | PATHOLOGY | Investigation | £17 |
| 84154 | Prostate specific antigen (PSA); free | PATHOLOGY | Investigation | £23 |
| 84165 | Protein electrophoresis, protein electrophoretic fractionation and quantitation (SPEP) (UPEP); blood, serum, urine | PATHOLOGY | Investigation | £17 |
| 84220 | Pyruvate kinase | PATHOLOGY | Investigation | £10 |
| 84234 | Receptor assay; progesterone | PATHOLOGY | Investigation | £17 |
| 84235 | Receptor assay; endocrine, other than estrogen or progesterone (specify hormone) | PATHOLOGY | Investigation | £17 |
| 84305 | Somatomedin, insulin like growth factor, IGF-1, IGF-2 | PATHOLOGY | Investigation | £24 |
| 84402 | Testosterone (T); free | PATHOLOGY | Investigation | £17 |
| 84403 | Testosterone (T); total | PATHOLOGY | Investigation | £17 |
| 84436 | Thyroxine; total (T-4) (T4) (TT4) | PATHOLOGY | Investigation | £13 |
| 84439 | Thyroxine; free (FT4) (FT-4) (Free T-4) | PATHOLOGY | Investigation | £13 |
| 84443 | Thyroid stimulating hormone (TSH) | PATHOLOGY | Investigation | £17 |
| 84445 | Thyroid stimulating immune globulins (TSI) | PATHOLOGY | Investigation | £33 |
| 84460 | Transferase, alanine aminotransferase (ALT) (ALAT) (SGPT) | PATHOLOGY | Investigation | £10 |
| 84466 | Transferrin | PATHOLOGY | Investigation | £17 |
| 84478 | Triglycerides (Tg); blood, serum | PATHOLOGY | Investigation | £10 |
| 84479 | Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR) | PATHOLOGY | Investigation | £17 |
| 84480 | Triiodothyronine; total (T3) (T-3) (TT-3) (TT3) | PATHOLOGY | Investigation | £17 |
| 84481 | Triiodothyronine; free (FT3) (free T-3) (T-3 Uptake) | PATHOLOGY | Investigation | £17 |
| 84482 | Triiodothyronine; reverse (T3) (T-3) | PATHOLOGY | Investigation | £17 |
| 84484 | Troponin, quantitative; Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT) | PATHOLOGY | Investigation | £21 |
| 84512 | Troponin, qualitative | PATHOLOGY | Investigation | £21 |
| 84520 | Urea nitrogen (BUN); blood, serum; quantitative | PATHOLOGY | Investigation | £13 |
| 84525 | Urea nitrogen; semiquantitative (eg, reagent strip test) | PATHOLOGY | Investigation | £13 |
| 84540 | Urea nitrogen; urine | PATHOLOGY | Investigation | £13 |
| 84545 | Urea nitrogen; clearance | PATHOLOGY | Investigation | £13 |
| 84550 | Uric acid; blood, serum | PATHOLOGY | Investigation | £10 |
| 84560 | Uric acid; other source | PATHOLOGY | Investigation | £10 |
| 84702 | Serum pregnancy, gonadotropin chorionic (hCG) (BetahCG); quantitative | PATHOLOGY | Investigation | £13 |
| 84703 | Urine pregnancy, gonadotropin chorionic (hCG) (BetahCG); qualitative | PATHOLOGY | Investigation | £10 |
| 84830 | Ovulation tests by visual color comparison methods for human luteinizing hormone (LH) (Ovutest) | PATHOLOGY | Investigation | £13 |
| 85007 | Blood count; manual differential WBC count (includes RBC morphology and platelet estimation) | PATHOLOGY | Investigation | £13 |
| 85008 | Blood count; manual blood smear examination without differential parameters (formerly code 85585) | PATHOLOGY | Investigation | £13 |
| 85009 | Blood count; differential WBC count, buffy coat | PATHOLOGY | Investigation | £13 |
| 85014 | Blood count; hematocrit, haematocrit (Hct) (Ht) | PATHOLOGY | Investigation | £13 |
| 85018 | Blood count; hemoglobin, haemoglobin (Hgb) (Hb) | PATHOLOGY | Investigation | £13 |
| 85025 | Blood count; hemogram and platelet count, automated and automated complete differential WBC count (CBC), haemogram, hematology, haematology | PATHOLOGY | Investigation | £13 |
| 85027 | Blood count; complete (CBC), hemogram, haemogram and platelet count, automated (Formerly codes 85021, 85022, 85023) | PATHOLOGY | Investigation | £13 |
| 85032 | Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each (formerly code 85590) | PATHOLOGY | Investigation | £13 |
| 85041 | Blood count; red blood cell (RBC) only | PATHOLOGY | Investigation | £13 |
| 85044 | Blood count; reticulocyte count, manual | PATHOLOGY | Investigation | £13 |
| 85045 | Blood count; automated, reticulocyte count, flow cytometry | PATHOLOGY | Investigation | £13 |
| 85046 | Blood count; reticulocytes, hemoglobin, haemoglobin concentration; automated, including one or more cellular parameters, immature reticulocyte fraction, reticulocyte volume, direct measurement | PATHOLOGY | Investigation | £13 |
| 85048 | Blood count; white blood cell (WBC), leukocyte count, leucocyte count, neutrophil count; automated | PATHOLOGY | Investigation | £13 |
| 85049 | Blood count; platelet count; thrombocyte count, automated (formerly codes 85595, 85598) | PATHOLOGY | Investigation | £13 |
| 85055 | Reticulated platelet assay | PATHOLOGY | Investigation | £13 |
| 85060 | Blood smear; peripheral, interpretation by physician | PATHOLOGY | Investigation | £230 |
| 85097 | Bone marrow, smear interpretation | PATHOLOGY | Investigation | £230 |
| 85210 | Clotting; factor II, prothrombin, specific | PATHOLOGY | Investigation | £22 |
| 85220 | Clotting; factor V, AcG or proaccelerin, labile factor, leiden factor | PATHOLOGY | Investigation | £22 |
| 85230 | Clotting; factor VII, proconvertin, stable factor | PATHOLOGY | Investigation | £22 |
| 85240 | Clotting; factor VIII, AHG | PATHOLOGY | Investigation | £22 |
| 85244 | Clotting; factor VIII related antigen | PATHOLOGY | Investigation | £22 |
| 85245 | Clotting; factor VIII, VW factor, Von Willebrand's factor, ristocetin cofactor | PATHOLOGY | Investigation | £22 |
| 85246 | Clotting; factor VIII, VW factor antigen, Von Willebrand's factor antigen | PATHOLOGY | Investigation | £22 |
| 85247 | Clotting; factor VIII, Von Willebrand's factor, multimetric analysis | PATHOLOGY | Investigation | £22 |
| 85250 | Clotting; factor IX, PTC,Christmas | PATHOLOGY | Investigation | £22 |
| 85260 | Clotting; factor X, Stuart-Prower | PATHOLOGY | Investigation | £22 |
| 85270 | Clotting; factor XI, PTA | PATHOLOGY | Investigation | £22 |
| 85280 | Clotting; factor XII, Hageman | PATHOLOGY | Investigation | £22 |
| 85290 | Clotting; factor XIII, fibrin stabilizing | PATHOLOGY | Investigation | £22 |
| 85292 | Clotting; prekallikrein assay, Fletcher factor assay | PATHOLOGY | Investigation | £20 |
| 85293 | Clotting; high molecular weight kininogen assay, Fitzgerald factor assay | PATHOLOGY | Investigation | £20 |
| 85300 | Clotting inhibitors or anticoagulants; antithrombin III | PATHOLOGY | Investigation | £20 |
| 85302 | Clotting inhibitors or anticoagulants; protein C, antigen | PATHOLOGY | Investigation | £20 |
| 85305 | Clotting inhibitors or anticoagulants; protein S, total and free | PATHOLOGY | Investigation | £20 |
| 85378 | Fibrin degradation products, D-dimer | PATHOLOGY | Investigation | £8 |
| 85384 | Fibrinogen; activity | PATHOLOGY | Investigation | £8 |
| 85385 | Fibrinogen; antigen | PATHOLOGY | Investigation | £43 |
| 85610 | Prothrombin time (PT) (Formerly code 85600) | PATHOLOGY | Investigation | £20 |
| 85651 | Sedimentation rate, erythrocyte (ESR) (SED); non-automated | PATHOLOGY | Investigation | £8 |
| 85670 | Thrombin time; plasma (TT) (TCT) (Thrombin clotting time) | PATHOLOGY | Investigation | £20 |
| 85705 | Thromboplastin inhibition; tissue (TTI) | PATHOLOGY | Investigation | £20 |
| 85730 | Thromboplastin time, partial (PTT) (aPTT); plasma or whole blood, serum | PATHOLOGY | Investigation | £20 |
| 85732 | Thromboplastin time, partial (PTT); substitution, plasma fractions, each | PATHOLOGY | Investigation | £20 |
| 85810 | Viscosity, viscosimeter | PATHOLOGY | Investigation | £20 |
| 86140 | C-reactive protein (CRP) | PATHOLOGY | Investigation | £13 |
| 86141 | C-reactive protein; high sensitivity (hsCRP) | PATHOLOGY | Investigation | £13 |
| 86146 | Beta 2 Glycoprotein I antibody, each | PATHOLOGY | Investigation | £18 |
| 86225 | Deoxyribonucleic acid (DNA) antibody (anti-D Nase-B); anti ds DNA | PATHOLOGY | Investigation | £166 |
| 86300 | Immunoassay for tumor antigen, quantitative; CA 15-3, CA 27-29, CA 19-9, CA 125, CA 50, CA 72-4, CA 549, each antigen | PATHOLOGY | Investigation | £17 |
| 86301 | Immunoassay for tumor antigen, quantitative; CA 19-9 | PATHOLOGY | Investigation | £17 |
| 86304 | Immunoassay for tumor antigen; quantitative, CA 125 | PATHOLOGY | Investigation | £17 |
| 86316 | Immunoassay for tumor antigen, tumor markers, quantitative; (eg, CA 15-3, CA 19-9, CA 50, CA 72-4, CA 125, CA 195, CA 242, CA 549) | PATHOLOGY | Investigation | £17 |
| 86320 | Immunoelectrophoresis; blood, serum | PATHOLOGY | Investigation | £17 |
| 86325 | Immunoelectrophoresis; other fluids (eg, urine, cerebrospinal fluid (CSF)) with concentration | PATHOLOGY | Investigation | £126 |
| 86334 | Immunofixation electrophoresis | PATHOLOGY | Investigation | £34 |
| 86335 | Immunofixation electrophoresis; serum; other fluids with concentration (eg, urine, CSF); or 24-hour urine; including monoclonal protein, M-protein | PATHOLOGY | Investigation | £126 |
| 86340 | Intrinsic factor antibodies (anti-IgF-I antibodies) | PATHOLOGY | Investigation | £17 |
| 86359 | T cells; total count | PATHOLOGY | Investigation | £20 |
| 86360 | T cells; absolute CD4 and CD8 count, including ratio | PATHOLOGY | Investigation | £98 |
| 86361 | T cells; absolute CD4 count (CD 4) (CD-4) | PATHOLOGY | Investigation | £98 |
| 86367 | Stem cells ( ie, CD34, CD 34, CD-34), total count using the different ways of writing CD34 (formerly code 86364) | PATHOLOGY | Investigation | £98 |
| 86376 | Microsomal antibodies (eg, thyroid or liver-kidney); each antibody (e.g. antimicrosomal, anti-liver-kidney microsomal (LKM)) | PATHOLOGY | Investigation | £33 |
| 86631 | Antibody; chlamydia, IgG, IgA | PATHOLOGY | Investigation | £12 |
| 86632 | Antibody; chlamydia, IgM | PATHOLOGY | Investigation | £12 |
| 86644 | Antibody; cytomegalovirus, IgG (CMV) | PATHOLOGY | Investigation | £89 |
| 86645 | Antibody; cytomegalovirus, IgM (CMV) | PATHOLOGY | Investigation | £89 |
| 86880 | Antihuman globulin test (Coombs test); direct | PATHOLOGY | Investigation | £11 |
| 86885 | Antihuman globulin test (Coombs test); indirect | PATHOLOGY | Investigation | £11 |
| 87149 | Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed | PATHOLOGY | Investigation | £166 |
| 87153 | Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16S rRNA gene) | PATHOLOGY | Investigation | £166 |
| 87177 | Ova and parasites, direct smears; concentration and identification | PATHOLOGY | Investigation | £230 |
| 87181 | Susceptibility/sensitivity studies, antibiotic; agar dilution method, agar diffusion method, per agent (eg, antibiotic gradient strip) | PATHOLOGY | Investigation | £29 |
| 87184 | Susceptibility/sensitivity studies, antibiotic; disk method, disc method, per plate (12 or fewer agents) | PATHOLOGY | Investigation | £29 |
| 87186 | Susceptibility/sensitivity studies, antibiotic; microdilution or agar dilution (minimum inhibitory concentration (MIC) or breakpoint), each multi-antimicrobial, per plate | PATHOLOGY | Investigation | £29 |
| 87187 | Susceptibility/sensitivity studies, antibiotic; microdilution or agar dilution, minimum lethal concentration (MLC), each plate | PATHOLOGY | Investigation | £29 |
| 87188 | Susceptibility/sensitivity studies, antibiotic; macrobroth dilution method, each agent | PATHOLOGY | Investigation | £29 |
| 87205 | Smear, primary source with interpretation; Gram Stain or Gi bacteria, fungi, or cell types | PATHOLOGY | Investigation | £230 |
| 87206 | Smear, primary source with interpretation; fluorescent stain for bacteria, fungi, parasites, viruses or cell types | PATHOLOGY | Investigation | £230 |
| 87207 | Smear, primary source with interpretation; special stain bodies or intracellular parasites (eg, malaria, coccidia microsporidia, cytomegalovirus, herpes viruses) | PATHOLOGY | Investigation | £230 |
| 87210 | Smear, primary source with interpretation; wet mount agents (eg, saline, India ink, KOH preps) | PATHOLOGY | Investigation | £230 |
| 87495 | Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus (CMV), direct probe technique | PATHOLOGY | Investigation | £48 |
| 87497 | Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus (CMV), quantification | PATHOLOGY | Investigation | £48 |
| 87506 | Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella Quintana, direct probe technique ; gastrointestinal pathogen, includes multiplex reverse transcription. | PATHOLOGY | Investigation | £48 |
| 87510 | Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique | PATHOLOGY | Investigation | £48 |
| 87516 | Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, amplified probe technique | PATHOLOGY | Investigation | £48 |
| 87517 | Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, quantification | PATHOLOGY | Investigation | £48 |
| 87521 | Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C amplified probe technique | PATHOLOGY | Investigation | £48 |
| 87522 | Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C quantification; HCV RNA, quantification | PATHOLOGY | Investigation | £48 |
| 87528 | Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, direct probe technique | PATHOLOGY | Investigation | £48 |
| 87534 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique | PATHOLOGY | Investigation | £48 |
| 87535 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, uncludes reverse transcription when performed | PATHOLOGY | Investigation | £48 |
| 87536 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed | PATHOLOGY | Investigation | £48 |
| 87537 | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique | PATHOLOGY | Investigation | £48 |
| 87555 | Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, direct probe technique | PATHOLOGY | Investigation | £48 |
| 87556 | Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique | PATHOLOGY | Investigation | £48 |
| 87557 | Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, quantification | PATHOLOGY | Investigation | £48 |
| 87623 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44) | PATHOLOGY | Investigation | £48 |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 ) | PATHOLOGY | Investigation | £48 |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed | PATHOLOGY | Investigation | £48 |
| 87631 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 3-5 targets | PATHOLOGY | Investigation | £48 |
| 87632 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 6-11 targets | PATHOLOGY | Investigation | £48 |
| 87633 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 12-25 targets | PATHOLOGY | Investigation | £48 |
| 87641 | Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique | PATHOLOGY | Investigation | £48 |
| 87798 | Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism (e.g. PCR BK virus, PCR JC virus); urine, plasma, or serum; quantitative | PATHOLOGY | Investigation | £48 |
| 87901 | Infectious agent genotype analysis by nucleic acid (DNA or RNA) HIV 1; reverse transcriptase and protease | PATHOLOGY | Investigation | £166 |
| 87902 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus | PATHOLOGY | Investigation | £166 |
| 87903 | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first 10 drugs tested | PATHOLOGY | Investigation | £166 |
| 87912 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis B virus | PATHOLOGY | Investigation | £166 |
| 88108 | Cytopathology, concentration technique, smears and interpretation (Saccomanno technique) | PATHOLOGY | Investigation | £230 |
| 88141 | Cytopathology, cervical or vaginal, PAP smear: Includes interpretation | PATHOLOGY | Investigation | £230 |
| 88160 | Cytopathology, smears excluding cervical or vaginal, any other source; screening and interpretation. | PATHOLOGY | Investigation | £230 |
| 88182 | Flow cytometry; cytoplasmic or nuclear marker; cell cycle or DNA analysis (Formerly code 88180) | PATHOLOGY | Investigation | £166 |
| 88271 | Molecular cytogenetics; DNA probe (eg, FISH) | PATHOLOGY | Investigation | £166 |
| 88313 | Special stains;Group II, all other, except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry. Reporting code R8313 | PATHOLOGY | Investigation | £22 |
| 88342 | Immunohistochemistry separately identifiable antibody per block, cytologic preparation, or hematologic smear; first separately identifiable antibody per slide: Reporting code R8342. | PATHOLOGY | Investigation | £230 |
| 88399 | Unlisted surgical pathology procedure (e.g. tumor biopsy) | PATHOLOGY | Investigation | £144 |
| 88720 | Bilirubin, total, transcutaneous | PATHOLOGY | Investigation | £13 |
| 89051 | Cell count, miscellaneous body fluids (eg, cerebrospinal fluid (CSF), joint fluid), except blood, serum; with differential count | PATHOLOGY | Investigation | £8 |
| 89190 | Eosinophil smear, eosinophil count; nasal, sputum, urine | PATHOLOGY | Investigation | £230 |
| 93268 | Auto activated electrocardiographic rhythm event recording with symptom-related memory loop with remote download capability up to 30 days; includes transmission, physician review and interpretation | PATHOLOGY | Investigation | £304 |
| 93270 | External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days. 24-hour attended monitoring; recording (includes connection, recording, and disconnection) | PATHOLOGY | Investigation | £304 |
| 93271 | External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days. 24-hour attended monitoring; transmission download and analysis | PATHOLOGY | Investigation | £304 |
| 93272 | External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days. 24-hour attended monitoring; physician review and interpretation | PATHOLOGY | Investigation | £304 |
| 93505 | Endomyocardial biopsy, myocardial biopsy | PATHOLOGY | Investigation | £213 |
| 95250 | Ambulatory glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for 72 hours; placement, calibration, training, removal and recording. Use 95251 for interpretation and report | PATHOLOGY | Investigation | £139 |
| 95251 | Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; interpretation and report | PATHOLOGY | Investigation | £139 |
| 81400-11 | F7 (coagulation factor VII [serum prothrombin conversion accelerator])(eg, hereditary hypercoagulability), R353Q variant. . | PATHOLOGY | Investigation | £20 |
| 81400-12 | FGB (fibrinogen beta chain) (eg, hereditary ischemic heart disease), -455G>A varian. . | PATHOLOGY | Investigation | £8 |
| 81400-16 | GNE (glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosaminekinase) (eg, inclusion body myopathy 2 [IBM2], Nonaka myopathy),M712T variant. . | PATHOLOGY | Investigation | £10 |
| 81400-17 | Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa],antigen CD61 [GPIIIa]), HPA-1a/b (L33P). . | PATHOLOGY | Investigation | £17 |
| 81400-18 | Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIba]), HPA-2a/b(T145M). . | PATHOLOGY | Investigation | £17 |
| 81400-19 | Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]), HPA-3a/b (I843S). . | PATHOLOGY | Investigation | £17 |
| 81400-20 | Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]), HPA-4a/b (R143Q). . | PATHOLOGY | Investigation | £17 |
| 81400-21 | Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] [GPIa]), HPA-5a/b (K505E). . | PATHOLOGY | Investigation | £17 |
| 81400-22 | Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]), HPA-6a/b (R489Q). . | PATHOLOGY | Investigation | £17 |
| 81400-23 | Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]), HPA-9a/b (V837M). . | PATHOLOGY | Investigation | £17 |
| 81400-24 | Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], posttransfusion purpura), HPA-15a/b (S682Y). . | PATHOLOGY | Investigation | £17 |
| 81400-27 | LCT (lactase-phlorizin hydrolase) (eg, lactose intolerance), 13910 C>Tvariant. . | PATHOLOGY | Investigation | £10 |
| 81401-02 | ABL (c-abl oncogene 1, receptor tyrosine kinase) (eg, acquired imatinib resistance), T315I variant | PATHOLOGY | Investigation | £10 |
| 81401-04 | ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) | PATHOLOGY | Investigation | £17 |
| 81401-06 | APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) | PATHOLOGY | Investigation | £13 |
| 81401-25 | DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy,type 1), evaluation to detect abnormal (eg, expanded) alleles. | PATHOLOGY | Investigation | £10 |
| 81401-51 | LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), commonvariants (eg, R1441G, G2019S, I2020T). | PATHOLOGY | Investigation | £10 |
| 81401-67 | PAX8/PPARG (t(2;3) (q13;p25)) (eg, follicular thyroid carcinoma),translocation analysis. | PATHOLOGY | Investigation | £33 |
| 81402-04 | ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer). Please reference general code 81402. | PATHOLOGY | Investigation | £24 |
| 81403-01 | ABL1 (c-abl oncogene 1, receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), variants in the kinase domain. Please reference general code 81403. | PATHOLOGY | Investigation | £10 |
| 81403-08 | DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukemia), targeted sequence analysis (eg, exon 23). Please reference general code 81403. | PATHOLOGY | Investigation | £166 |
| 81403-18 | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12sequence and exon 13 sequence, if Performed | PATHOLOGY | Investigation | £10 |
| 81403-23 | Known familial variant not otherwise specified, for gene listed in Tier 1 or Tier 2, DNA sequence analysis, each variant exon. Please reference general code 81403. | PATHOLOGY | Investigation | £166 |
| 81404-08 | C10orf2 (chromosome 10 open reading frame 2) (eg, mitochondrial DNAdepletion syndrome), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81404-10 | CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence. Please reference general code 81404. | PATHOLOGY | Investigation | £126 |
| 81404-11 | CDKN2A (cyclin-dependent kinase inhibitor 2A)(eg, CDKN2A-related cutaneous malignant melanoma, familial atypicalmole-malignant melanoma syndrome), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81404-18 | DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophytype 1), characterization of abnormal (eg, expanded) alleles. Please reference general code 81404. | PATHOLOGY | Investigation | £119 |
| 81404-66 | RET (ret proto-oncogene) (eg, multiple endocrine neoplasia, type 2B andfamilial medullary thyroid carcinoma), common variants (eg, M918T,2647_2648delinsTT, A883F). Please reference general code 81404. | PATHOLOGY | Investigation | £142 |
| 81404-75 | SLC16A2 (solute carrier family 16, member 2 [thyroid hormonetransporter]) (eg, specific thyroidhormone cell transporter deficiency, Allan-Herndon-Dudley syndrome),duplication/deletion analysis. | PATHOLOGY | Investigation | £142 |
| 81404-80 | STK11 (serine/threonine kinase 11) (eg, Peutz-Jeghers syndrome),duplication/deletion analysis | PATHOLOGY | Investigation | £10 |
| 81405-107 | SLC16A2 (solute carrier family 16, member 2 [thyroid hormonetransporter]) (eg, specific thyroid hormone cell transporterdeficiency, Allan-Herndon-Dudley syndrome), full gene sequence | PATHOLOGY | Investigation | £142 |
| 81405-11 | BMPR2 (bone morphogenetic protein receptor, type II[serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis | PATHOLOGY | Investigation | £119 |
| 81405-110 | SLC2A1 (solute carrier family 2 [facilitated glucose transporter],member 1) (eg, glucose transporter type 1 [GLUT 1] deficiencysyndrome), full gene sequence. Please reference general code 81405. | PATHOLOGY | Investigation | £115 |
| 81405-117 | STK11 (serine/threonine kinase 11) (eg, Peutz-Jeghers syndrome),full gene sequence | PATHOLOGY | Investigation | £119 |
| 81405-119 | TARDBP (TAR DNA binding protein) (eg, amyotrophic lateral sclerosis), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81405-124 | THRB (thyroid hormone receptor, beta) (eg, thyroid hormoneresistance, thyroid hormone beta receptor deficiency), full gene sequence or targeted sequence analysis of >5 exons. | PATHOLOGY | Investigation | £142 |
| 81405-125 | TK2 (thymidine kinase 2, mitochondrial) (eg, mitochondrial DNAdepletion syndrome), full gene sequence | PATHOLOGY | Investigation | £175 |
| 81405-126 | TNNI3 (troponin I, type 3 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence | PATHOLOGY | Investigation | £131 |
| 81405-127 | TNNC1 (troponin C type 1 [slow]) (eg, hypertrophic cardiomyopathy or dilated cardiomyopathy), full gene sequence | PATHOLOGY | Investigation | £131 |
| 81405-131 | TYMP (thymidine phosphorylase) (eg, mitochondrial DNA depletionsyndrome), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81405-14 | CDKL5 (cyclin-dependent kinase-like 5) (eg, earlyinfantile epileptic encephalopathy), duplication/deletion analysis. Please reference general code 81405. | PATHOLOGY | Investigation | £119 |
| 81405-28 | DGUOK (deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence | PATHOLOGY | Investigation | £175 |
| 81405-29 | DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-Lemli-Opitzsyndrome), full gene sequence | PATHOLOGY | Investigation | £122 |
| 81405-61 | MPV17 (MpV17 mitochondrial inner membrane protein) (eg,mitochondrial DNA depletion syndrome), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81405-77 | OTC (ornithine carbamoyltransferase) (eg, ornithine transcarbamylasedeficiency), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81405-84 | PINK1 (PTEN induced putative kinase 1) (eg, Parkinson disease), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81405-93 | RET (ret proto-oncogene) (eg, multiple endocrine neoplasia, type 2A and familial medullary thyroid carcinoma), targeted sequence analysis (eg,exons 10, 11, 13-16) | PATHOLOGY | Investigation | £142 |
| 81405-95 | RRM2B (ribonucleotide reductase M2 B [TP53 inducible]) (eg,mitochondrial DNA depletion), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81406-112 | POLG (polymerase [DNA directed], gamma) (eg, Alpers-Huttenlochersyndrome, autosomal dominant progressive external ophthalmoplegia), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81406-116 | PRKAG2 (protein kinase, AMP-activated, gamma 2 non-catalytic subunit) full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-117 | PRKCG (protein kinase C, gamma) (eg, spinocerebellar ataxia), full gene sequence (sodium channel,voltage-gated, type IV, alpha subunit) (eg,hyperkalemic periodic paralysis), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-134 | SLC37A4 (solute carrier family 37 [glucose-6-phosphate transporter],member 4) (eg, glycogen storage disease type Ib), full gene sequence | PATHOLOGY | Investigation | £115 |
| 81406-144 | TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophiccardiomyopathy), full gene sequence | PATHOLOGY | Investigation | £131 |
| 81406-16 | BMPR2 (bone morphogenetic protein receptor, type II [serine/threoninekinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-19 | BTK (Bruton agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-24 | CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epilepticencephalopathy), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-25 | CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-26 | CLCNKB (chloride channel, voltage-sensitive Kb) (eg, Bartter syndrome 3 and 4b), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-47 | FASTKD2 (FAST kinase domains 2) (eg, mitochondrial respiratory chaincomplex IV deficiency), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-56 | GCK (glucokinase [hexokinase 4]) (eg, maturity-onset diabetes of theyoung [MODY]), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-58 | GNE (glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosaminekinase) (eg, inclusion body myopathy 2 [IBM2], Nonaka myopathy), fullgene sequence | PATHOLOGY | Investigation | £119 |
| 81406-80 | MAP2K1 (mitogen-activated protein kinase 1) (eg, cardiofaciocutaneoussyndrome), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81406-81 | MAP2K2 (mitogen-activated protein kinase 2) (eg, cardiofaciocutaneoussyndrome), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81407-06 | CHD7 (chromodomain helicase DNA binding protein 7) (eg, CHARGEsyndrome), full gene sequence | PATHOLOGY | Investigation | £275 |
| 81407-31 | SLC12A1 (solute carrier family 12 [sodium/potassium/chloride transporters], member 1) (eg, Bartter syndrome), full gene sequence. Please reference general code 81407. | PATHOLOGY | Investigation | £119 |
| 81407-32 | SLC12A3 (solute carrier family 12 [sodium/chloride transporters], member 3) (eg, Gitelman syndrome), full gene sequence | PATHOLOGY | Investigation | £119 |
| 81408-17 | LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence. Please reference general code 81408. | PATHOLOGY | Investigation | £10 |
| INR | International Normalized Ratio (INR) | PATHOLOGY | Investigation | £12 |
| NIHR_INV_025 | Skin Scrape | PATHOLOGY | Investigation | £673 |
| NIHR_INV_026 | Brochial wash | PATHOLOGY | Investigation | £636 |
| NIHR_INV_027 | Paraprotein Measurement (Densitometry) | PATHOLOGY | Investigation | £17 |
| T0060 | Thyroid panel, thyroid function tests - Includes triiodothyronine, T3 (84480) thyroxine, T4 (84436) thyroid stimulating hormone, TSH (84443) (Formerly QuintilesIMS code 80060) | PATHOLOGY | Investigation | £23 |
| T0065 | Lipid Panel II: Includes Total Cholesterol, Lipoprotein, high density cholesterol (HDL cholesterol), low density cholesterol (LDL Cholesterol), Triglycerides, Apolipoprotein (Apo A-1) (Apo B) (Apo E) | PATHOLOGY | Investigation | £23 |
| T0073 | Hepatitis panel - Includes hepatitis B and C only (Formerly QuintilesIMS code 80073) | PATHOLOGY | Investigation | £12 |
| T0090 | TORCH antibody panel: Includes Antibody, cytomegalovirus (CMV) (86644) Antibody, herpes simplex, non-specific type test (86694) Antibody, rubella (86762) Antibody, toxoplasma (86777) | PATHOLOGY | Investigation | £12 |
| T0095 | Endocrine panel - Includes cortisol (82533) human growth hormone, HGH (83003) prolactin, PRL (84146) adrenocorticotropic hormone, ACTH (82024) (Formerly QuintilesIMS code 80095) | PATHOLOGY | Investigation | £39 |
| T0217 | Anesthesia for all procedures on esophagus, thyroid, larynx, trachea and lymphatic system of neck; needle biopsy of thyroid | PATHOLOGY | Intervention includes Investigation (where applicable) | £1,085 |
| T0719 | Cardiac Telemetry; continuous electronic monitoring of heart rhythm and heart rate, with or without blood pressure monitoring; 0-6 hours | PATHOLOGY | Investigation | £110 |
| T0720 | Cardiac Telemetry; continuous electronic monitoring of heart rhythm and heart rate, with or without blood pressure monitoring; up to 24 hours: Includes interpretation and report | PATHOLOGY | Investigation | £110 |
| T0908 | Cystic Fibrosis Screen by PCR; Oligonucleotide Ligation: ACOG Panel | PATHOLOGY | Investigation | £92 |
| T0911 | Anemia Profile Panel including reticulocyte count, Iron with TIBC, Vitamin B12, CBC with differential, Ferritin, Folate, Folic Acid | PATHOLOGY | Investigation | £23 |
| T1013 | Comprehensive Anemia Profile, Anaemia Panel including: reticulocyt count, Iron with TIBC, Vitamin B12, CBC with differential, ferritin, folate, folic acid. | PATHOLOGY | Investigation | £23 |
| T1103 | Autoimmune Panel, up to five indicators | PATHOLOGY | Investigation | £23 |
| T1104 | Autoimmune Panel, up to 10 indicators | PATHOLOGY | Investigation | £47 |
| T1105 | Autoimmune Panel, up to 15 indicators | PATHOLOGY | Investigation | £70 |
| T1201 | KRAS gene, 7 mutation panel, Tumor ; c-K-ras2 protein; c-K-ras protein; KI-RAS; Kirsten rat sarcoma-2 viral (v-Ki-ras2) oncogene homolog: For interpretation and report use RT201 | PATHOLOGY | Investigation | £23 |
| T1203 | Jak2 (V617F) Mutation by PCR | PATHOLOGY | Investigation | £92 |
| T1208 | Two-dimensional gel electrophoresis, staining, digitizing and quantification of known protein | PATHOLOGY | Investigation | £17 |
| T4186 | IgF binding protein 1 (IGFBP-1) (IGFBP1) (IGFBP 1) (Formerly QuintilesIMS code 84186) | PATHOLOGY | Investigation | £17 |
| T4187 | IgF binding protein 3 (IGFBP-3) (IGFBP3) (IGFBP 3) (Formerly QuintilesIMS code 84187) | PATHOLOGY | Investigation | £17 |
| T5209 | Clotting; factor I, fibrinogen (Formerly QuintilesIMS code 85209) | PATHOLOGY | Investigation | £27 |
| T6362 | T cells; absolute CD8 count (CD 8) (CD-8) (Formerly QuintilesIMS code 86362) | PATHOLOGY | Investigation | £20 |
| T6363 | CD18, CD 18, CD-18 (Formerly QuintilesIMS code 86363) | PATHOLOGY | Investigation | £20 |
| T6365 | Earliest B cells CD19, CD 19, CD-19 (Formerly QuintilesIMS code 86365) | PATHOLOGY | Investigation | £20 |
| T9013 | Biopsy; Staining and preparation of the slides including shipping and handling (Formerly QuintilesIMS code 99013) | PATHOLOGY | Investigation | £54 |
| T9999 | Unlisted laboratory panel, safety labs, routine laboratory tests; chemistry, chemistries, smac, hemogram, hematology, CBC, urinalysis, urine analysis (Formerly QuintilesIMS code 89999) | PATHOLOGY | Investigation | £23 |
| TM030 | Biomarker, Intercellular adhesion molecule 1 (ICAM-1) (sICAM-1) (CD54) (CD 54) (CD-54) (Formerly QuintilesIMS code BM030) | PATHOLOGY | Investigation | £20 |
| TM035 | Biomarker, Dipeptidyl peptidase-IV, dipeptidyl peptidase 4 (DPP-IV) (DPP IV) (CD26) (CD 26) (CD-26) (Formerly QuintilesIMS code BM035) | PATHOLOGY | Investigation | £20 |
| TM038 | Biomarker, Prothrombin fragments 1 and 2, Prot 1+2 (Formerly QuintilesIMS code BM038) | PATHOLOGY | Investigation | £20 |
| TM039 | Biomarker, Tumor block immunohistochemistry (IHC), oncology marker (Formerly QuintilesIMS code BM039) | PATHOLOGY | Investigation | £80 |
| TM040 | Biomarker, Tumor block immunohistochemistry (IHC), oncology marker with imaging (Formerly QuintilesIMS code BM040) | PATHOLOGY | Investigation | £80 |
| 70200 | X-RAY 1 view | RADIOLOGY | Investigation | £61 |
| 70220 | X-RAY 3 views | RADIOLOGY | Investigation | £183 |
| 70300 | X-RAY Per view | RADIOLOGY | Investigation | £43 |
| 70450 | CT Scan without contrast 1 site | RADIOLOGY | Investigation | £169 |
| 70460 | CT Scan with contrast 1 site | RADIOLOGY | Investigation | £257 |
| 70540 | MRI/MRA with or without contrast 1 site | RADIOLOGY | Investigation | £491 |
| 70554 | MRI Complex | RADIOLOGY | Investigation | £635 |
| 70555 | Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional: Reporting code R0555 | RADIOLOGY | Intervention includes Investigation (where applicable) | £1,433 |
| 71020 | X-RAY 2 views | RADIOLOGY | Investigation | £122 |
| 71023 | X-RAY Complex (Biopsy guidance or Skeletal Survey) | RADIOLOGY | Investigation | £366 |
| 71555 | MRI/MRA with contrast 4 sites or more/ whole body | RADIOLOGY | Investigation | £1,155 |
| 72050 | X-RAY 5 views | RADIOLOGY | Investigation | £305 |
| 72052 | X-RAY 6 views | RADIOLOGY | Investigation | £366 |
| 72141 | MRI/MRA with or without contrast 1 site | RADIOLOGY | Investigation | £491 |
| 72240 | Myelography | RADIOLOGY | Investigation | £274 |
| 72295 | Diskography, lumbar, radiological supervision, nucleography | RADIOLOGY | Investigation | £181 |
| 73564 | X-RAY 4 views | RADIOLOGY | Investigation | £244 |
| 74176 | CT Scan without contrast 2 Sites | RADIOLOGY | Investigation | £267 |
| 74177 | CT Scan with contrast 4 sites or more/ whole body | RADIOLOGY | Investigation | £514 |
| 74246 | X-RAY with contast per visit | RADIOLOGY | Investigation | £183 |
| 74290 | Cystography | RADIOLOGY | Investigation | £601 |
| 74420 | Urography, retrograde, with or without KUB; Reporting code R4420 | RADIOLOGY | Investigation | £138 |
| 75561 | MRI Complex - novel sequences requiring development | RADIOLOGY | Investigation | £635 |
| 75635 | CT Scan with contrast 3 sites | RADIOLOGY | Investigation | £378 |
| 75820 | X-RAY Venography | RADIOLOGY | Investigation | £92 |
| 76442 | Ultrasound per site | RADIOLOGY | Investigation | £92 |
| 76498 | MRI/MRA without contrast 4 sites or more/ whole body | RADIOLOGY | Investigation | £1,027 |
| T1009 | CT Scan without contrast 4 sites or more/ whole body | RADIOLOGY | Investigation | £418 |
| T1021 | Ultrasound Complex / Developmental / Contrast-enhanced Ultrasound | RADIOLOGY | Investigation | £204 |
| T4169 | CT Scan with contrast 2 Sites | RADIOLOGY | Investigation | £337 |
| 77261 | Therapeutic radiology treatment planning; simple | RADIOTHERAPY | Investigation | £463 |
| 77262 | Therapeutic radiology treatment planning; intermediate | RADIOTHERAPY | Investigation | £700 |
| 77263 | Therapeutic radiology treatment planning; complex | RADIOTHERAPY | Investigation | £2,168 |
| 77280 | Therapeutic radiology simulation-aided field setting; simple; For Interpretation and Report please use code R7280 | RADIOTHERAPY | Investigation | £628 |
| 77285 | Therapeutic radiology simulation-aided field setting; intermediate; For Interpretation and Report please use code R7285 | RADIOTHERAPY | Investigation | £1,074 |
| 77290 | Therapeutic radiology simulation-aided field setting; complex; For Interpretation and Report please use code R7290 | RADIOTHERAPY | Investigation | £3,199 |
| 77300 | Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose | RADIOTHERAPY | Investigation | £3,199 |
| NIHR_INV_032 | Deliver a Fraction of Treatment on a Superficial or Orthovoltage Machine | RADIOTHERAPY | Investigation | £182 |
| NIHR_INV_033 | Deliver a Fraction of Treatment on a Megavoltage Machine | RADIOTHERAPY | Investigation | £234 |
| NIHR_INV_034 | Deliver a Fraction of Complex Treatment on a Megavoltage Machine | RADIOTHERAPY | Investigation | £300 |
| NIHR_INV_035 | Deliver a Fraction of Radiotherapy on a Megavoltage Machine using General Anaesthetic | RADIOTHERAPY | Investigation | £545 |
| NIHR_INV_036 | Deliver a Fraction of Total Body Irradiation | RADIOTHERAPY | Investigation | £861 |
| NIHR_INV_037 | Deliver a Fraction of Adaptive Radiotherapy on a Megavoltage Machine | RADIOTHERAPY | Investigation | £391 |
| NIHR_INV_038 | Preparation for Intensity Modulated Radiation Therapy | RADIOTHERAPY | Investigation | £2,399 |
| NIHR_INV_039 | Preparation for Intensity Modulated Radiation Therapy, with Technical Support | RADIOTHERAPY | Investigation | £3,199 |
| NIHR_INV_040 | Preparation for Total Body Irradiation | RADIOTHERAPY | Investigation | £2,168 |
| NIHR_INV_041 | Preparation for Total Body Irradiation, with Technical Support | RADIOTHERAPY | Investigation | £2,168 |
| NIHR_INV_042 | Preparation for Hemi Body Irradiation | RADIOTHERAPY | Investigation | £671 |
| NIHR_INV_043 | Preparation for Simple Radiotherapy with Imaging and Dosimetry | RADIOTHERAPY | Investigation | £964 |
| NIHR_INV_044 | Preparation for Simple Radiotherapy with Imaging and Dosimetry, with Technical Support | RADIOTHERAPY | Investigation | £1,643 |
| NIHR_INV_045 | Preparation for Simple Radiotherapy with Imaging and Simple Calculation | RADIOTHERAPY | Investigation | £700 |
| NIHR_INV_046 | Preparation for Simple Radiotherapy with Imaging and Simple Calculation, with Technical Support | RADIOTHERAPY | Investigation | £1,074 |
| NIHR_INV_047 | Preparation for Superficial Radiotherapy with Simple Calculation | RADIOTHERAPY | Investigation | £463 |
| NIHR_INV_048 | Preparation for Superficial Radiotherapy with Simple Calculation, with Technical Support | RADIOTHERAPY | Investigation | £628 |
| NIHR_INV_049 | Preparation for Complex Conformal Radiotherapy | RADIOTHERAPY | Investigation | £1,445 |
| NIHR_INV_050 | Preparation for Complex Conformal Radiotherapy, with Technical Support | RADIOTHERAPY | Investigation | £1,926 |
| NIHR_INV_051 | All additionally required reports and interpretations (over and above standard care) per report | REPORTING | Investigation | £117 |
| 82800 | Gases, blood, pH only | SPECIALIST MEDICINE | Investigation | £58 |
| 82803 | Gases, blood, arterial blood gases (any combination of pH, pCO2, pO2, CO2, HCO3) | SPECIALIST MEDICINE | Investigation | £58 |
| 82805 | Gases, blood, arterial blood gases (any combination of pH, pCO2 calculated O2 saturation); with O2 saturation, by direct measurement except pulse oximetry | SPECIALIST MEDICINE | Investigation | £58 |
| 82810 | Gases, blood, O2 saturation only; by direct measurement, except pulse oximetry | SPECIALIST MEDICINE | Investigation | £58 |
| 92512 | Nasal function studies (eg, rhinomanometry, rhinoprobe, nasal CDA) | SPECIALIST MEDICINE | Investigation | £58 |
| 94010 | Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), forced expiratory volume (FEV), with or without maximal voluntary ventilation (MVV). Reporting code R4010. | SPECIALIST MEDICINE | Investigation | £215 |
| 94060 | Bronchospasm evaluation: spirometry with reversibility, pre- and post-bronchodilator administration (aerosol or parenteral), pulmonary function test (PFT), lung function test | SPECIALIST MEDICINE | Investigation | £95 |
| 94150 | Total vital capacity, pulmonary function test (PFT), lung function test | SPECIALIST MEDICINE | Investigation | £88 |
| 94729 | Diffusing capacity (eg, carbon monoxide, membrane) | SPECIALIST MEDICINE | Investigation | £86 |
| 95004 | Percutaneous tests (scratch, puncture, skin prick) with allergenic extracts, immediate type reaction, specify number of tests; includes interpretation and report | SPECIALIST MEDICINE | Investigation | £57 |
| 95070 | Inhalation bronchial challenge testing (not including necessary pulmonary function tests); with histamine, methacholine, or similar compounds; The reaction is documented | SPECIALIST MEDICINE | Investigation | £198 |
| 95071 | Inhalation bronchial challenge testing (not including necessary pulmonary function tests); with antigens or gases, specify | SPECIALIST MEDICINE | Investigation | £58 |
| 95806 | Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement): Reporting code R5806 | SPECIALIST MEDICINE | Investigation | £653 |
| 95808 | Polysomnography (PSG); sleep staging with 1-3 additional parameters of sleep, attended by a technologist; Reporting code R5808. | SPECIALIST MEDICINE | Investigation | £1,050 |
| 95819 | Electroencephalogram (EEG) including recording awake and asleep (including hyperventilation and/or photic stimulation when appropriate): Reporting code R5819 | SPECIALIST MEDICINE | Investigation | £653 |
| 95827 | Electroencephalogram (EEG); all night sleep only: Reporting code R5827 | SPECIALIST MEDICINE | Investigation | £653 |
| 96002 | Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles | SPECIALIST MEDICINE | Investigation | £89 |
| NIHR_INV_028 | Flow Volume Loop | SPECIALIST MEDICINE | Investigation | £70 |
| NIHR_INV_029 | Body Box Lung Volume | SPECIALIST MEDICINE | Investigation | £99 |
| NIHR_INV_030 | Gas Transfer/ DLCO/ Transfer Factor | SPECIALIST MEDICINE | Investigation | £70 |
| NIHR_INV_031 | Cough Challenge | SPECIALIST MEDICINE | Investigation | £198 |
| S0823 | 6 Minute Walk Test (6MWT) (6-MWT) | SPECIALIST MEDICINE | Investigation | £89 |
| S0857 | Short Physical Performance Battery, SPPB, assessment of lower extremity function, performance and mobility disability; includes standing and gait | SPECIALIST MEDICINE | Investigation | £89 |
| T5057 | Diagnostic photography, global photography (Formerly QuintilesIMS code 95057) | SPECIALIST MEDICINE | Investigation | £276 |
| Workbook content: | |||||
| This tariff has been created to assist both Industry and NHS partners to create consistent and meaningful costings for Industry sponsored research within the NHS. | |||||
| Values within this tariff do not include the relevant labour time required by research staff to initiate, carry out or report on the activity described. | |||||
| All values include an indirect cost and capacity building and therefore only need the addition of the local PbR MFF from the Industry Costing Tool to produce valid figures. | |||||
| Please note that all values included below are guidelines and may require adaptaion due to complexity, additional staff involvement or eternal third party contracts. | |||||
| All entries contain the following: | |||||
| ● Grantplan or NIHR Coding - Codes from the Industry Grantplan software or NIHR coding (for reference) where Grantplan coding is absent. | |||||
| ● Activity Description - Brief Description of activity taking place | |||||
| ● Specialty - Defined service support specialty that covers the activity (this may vary from one NHS organisation to another. | |||||
| ● Notes - Whether the activity is a single investigation, an intervention with associated investigation or a unit cost activity at setup or during the project. | |||||
| ● 2022/23 Costs - The defined unitary cost for the activity including an indirect element | |||||
| ● Definition - Any desciptor to identify the reasons behind a value or group of batched values | |||||
| Please note that these are NHS costs only and do not represent costs provided by commercial or academic units. A degree of consideration will be required in order to cost any of these items in conjunction with external NHS SLAs contract to either of these entities. | |||||
| The following tasks are deemed as part of the business service and are considered included in costs already in the costing template and therefore are NOT independently chargeable: | |||||
| - Set-up of any finance and IT information systems as required | |||||
| - Invoice generation for all departments | |||||
| - Any standard tasks performed by the Trust as part of normal or routine patient care | |||||
| - Any trial related communications | |||||
| - Any standard administrative or management support and general maintenance of trial related paperwork (NOTE: this EXCLUDES data management) | |||||
| - Pre-site selection or feasibility tasks | |||||
| - Arrange/attend any introduction or qualification meetings | |||||
| - Time research time spend preparing or attending inspections by regulatory bodies | |||||
| - Time for any regulatory body inspections | |||||
| - Medical record retrieval | |||||
| - Internal contracts or paperwork for staff i.e. honorary contracts or University – Trust agreements for research staff | |||||
| - PI duty of care responsibilities including Investigator review of safety reporting provided by COMPANY e.g. annual safety reports | |||||
| - Storage space/co-ordination of equipment/notes | |||||
| - Pre-screening (e.g. note searches) for non-stratified medicine/rare disease studies, however cost coverage for stratified medicine rare disease/study pre-screening resulting in significant workload for the participating organisation (e.g. data not recorded in routine patient notes) to be agreed on a study-by-study basis as required. | |||||
| - Company audits (if necessary Company and Trust can negotiate a cost for a company requested audit with above-standard time requirements for staff involved) | |||||
| Grantplan or NIHR Coding | Activity Description | Department | Notes | 2022/23 | Definition |
| NIHR_DEPT_001 | General R&D fee | General Departments | Setup | £1,096 | Costing and model agreement negotiation across organisation for final agreement, including any sub-contracts/service level agreement/honorary contracts as required. Coordination of practical arrangements for confirmation of local capability and capacity across the organisation as required by HRA Approval. Further information is available in the CRN principles of good practice (link to be included to document). NOTE: Assessment is considered part of site selection and covered by the indirect and capacity building elements of the template. Research management activities, such as investigator file set-up and maintenance, including performance oversight for set-up and recruitment activities to deliver contracted requirements. Co-ordination of all close-down activities across the organisation to met Sponsor requirements. Provision of general support for Sponsor to understand organisation requirements in context of UK research environment. Local CRN team is available to provide support as required (link to contacts on website) Variations to value (increase or decrease) may occur in relation to study or therapy area complexity. The base calculated figure is based upon 30 hours setup time required by Managerial and administrative grade staff |
| NIHR_DEPT_002 | Archiving fee (per box) to be paid upon completion of study | General Departments | Closedown | £549 | Per box fee provided for paper archiving by research site for a minimum duration of at least 15 years unless stated otherwise stated. The study specific archive duration is defined by the Sponsor for that study type and where the Clinical Trials Regulation (CTR) EU No 536/2014 is applicable may be at least 25 years. Total charge is expected to be appropriately described in the model agreement financial appendix payment schedule to reflect volume/ required duration relevant for the study. Fee covers archiving preparation (including site archivist review where necessary), transfer, retrieval, access, indefinite storage and destruction (when instructed by Sponsor at end of agreed archive period) of site related trial material. Where site utilises an external third party archive, clarification of activities included in any quote should be provided to the Sponsor and the site’s archiving preparation activities in such circumstances should be covered through the indirect/capacity building elements. Where the Sponsor takes responsibility for study archiving the fee should not be charged and the site’s archiving preparation activities in such circumstances should be covered through the indirect/capacity building elements. THE COST STATED HERE IS AN ECEONOMY OF SCALE BASED UPON AN AVERAGE OF 3 ARCHVING BOXES BEING REQUIRED. USERS SHOULD NOTE THAT A REQUIREMENT FOR LESS THAN 3 BOXES MAY RESULT IN A HIGHER COST PER BOX. |
| NIHR_DEPT_003 | Chief Investigator fee | General Departments | Setup | £1,594 | The Chief Investigator has additional tasks covered by this fee which are associated with: Ethics and MHRA review of documents Ethics submission Ethics meeting attendance Liaison with ethics assessment team Attendance at safety meetings throughout study Submission of Annual Progress Reports/ Development Safety Update Reports Provision of general medical oversight throughout the study including key teleconferences, Trial management, steering committee meetings to lead on study issues. Administration support time for activities listed above. If Chief Investigator involvement is only signature of Ethics form, this fee is not chargeable Further activities, especially prior to site selection, should be considered as a separate consultancy service which is not covered in this fee. A separate consultancy contract/costing is recommended. |
| NIHR_DEPT_004 | Clinical Research Facility set-up fee (only chargeable when specialist CRF is required for trial conduct or Sponsor has chosen to use facilities for potential study benefits) | General Departments | Setup | £1,535 | CRF is not part of standard patient care pathway and thus this resource space in Trusts must be paid for if required The fee is payable if: -The Specialist CRF required for trial conduct -The company/Sponsor has chosen to use CRF due to potential recruitment benefit No fee should be incurred by Company/Sponsor if Trust encounter capacity restraints and the use of the CRF is only option to retain the study or if there is minimal involvement e.g. room only use (this cost is covered by the indirect costs and should be distributed by the Trust to the CRF) The fees covers preliminary meetings with the CRF, study review, development, planning, set-up, delivery management and close down. |
| NIHR_DEPT_005 | Category A or B amendment fee (chargeable per amendment) | General Departments | In Flight | £313 | Only chargeable for category A or B amendments at that site requiring a change in documentation or process to conduct the study. Includes Review/implementation time by all relevant staff/departments for implementation, review and distribution. |
| NIHR_DEPT_006 | Training Fee (per hour per attending staff member) to be paid upon completion of training visits | General Departments | Setup | £81 | |
| NIHR_DEPT_007 | Monitoring Fee (per hour per attending staff member) to be paid quarterly in arrears | General Departments | In Flight | £81 | |
| NIHR_DEPT_008 | Set-up fee per Patient Inclusion Centre (PIC) used by site | General Departments | Setup | £274 | Patient Identification Centre (PIC) payments, including hub and spoke models, for GP surgeries must be based on work performed with consideration for timeframes and can be capped using relevant wording in the financial arrangements in the contract. Tasks involved are, but not limited to: • Database searches • Letter generation (packaging and postage excluded from fee and should be reimbursed as relevant to volume) • Patient follow-up including follow-up of non-responders (if covered in ethics application) • Tracking The guide fee assumes standard charge for note searches but could increase for complex searches or requires large numbers of letter generated. The base calculated figure is based upon 3 hours setup time required by Medical and administrative grade staff. The separate screening fee per randomised patient covers any source data verification work or support work the referral may require in relation to participation in the research. This should only be charged where additional work to that covered under the set-up tasks is required for the patient to participate |
| NIHR_DEPT_009 | Successful screening fee per randomised patient at PIC to be paid quarterly in arrears | General Departments | In Flight | £55 | The base calculated figure is based upon 0.5 hours time required by Medical and administrative grade staff. |
| NIHR_DEPT_010 | Refreshments for Patients (applicable for visits lasting over 3 hours) to be paid quarterly in arrears - Study Subject Related Expenses and Allowances | General Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_011 | Refreshments for Carers (applicable for visits lasting over 3 hours) to be paid quarterly in arrears - Study Subject Related Expenses and Allowances | General Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_012 | Inconvenience payment for patients as agreed by ethics to be paid quarterly in arrears - Study Subject Related Expenses and Allowances | General Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_013 | Maximum patient travel costs per visit* to be paid quarterly in arrears - Study Subject Related Expenses and Allowances | General Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_014 | Expenses for chief investigator attendance at Ethics meeting | General Departments | Setup | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_015 | Audiology Departments Setup | Audiology Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_016 | Cardiovascular Departments Setup | Cardiovascular Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_017 | Dental Departments Setup | Dental Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_018 | Genetics Departments Setup | Genetics Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_019 | Immunology or Virology Departments Setup | Immunology or Virology Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_020 | Interventional Diagnostics Departments Setup | Interventional Diagnostics Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_021 | Microbiology Departments Setup | Microbiology Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_022 | Nuclear Medicine Departments Setup | Nuclear Medicine Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_023 | Ophthalmology Departments Setup | Ophthalmology Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_024 | Radiology Additional scanning reports (e.g. RECIST, iRECIST etc) to be paid quarterly in arrears | Radiology Departments | In Flight | £140 | |
| NIHR_DEPT_025 | Radiology CRE Assessment | Radiology Departments | Setup | £274 | |
| NIHR_DEPT_026 | Radiology MPE Assessment | Radiology Departments | Setup | £274 | |
| NIHR_DEPT_027 | Radiology Phantom MRI Scans (inc Radiographer Training Time) | Radiology Departments | Setup | £580 | |
| NIHR_DEPT_028 | Radiology Phantom CT Scans (inc Radiographer Training Time) | Radiology Departments | Setup | £350 | |
| NIHR_DEPT_029 | Radiology Imaging Transfer to CD or Sponsor provided Soft or Hardware to be paid quarterly in arrears | Radiology Departments | In Flight | £32 | |
| NIHR_DEPT_030 | Radiology extending working hours (per hour) to be paid quarterly in arrears | Radiology Departments | In Flight | £81 | Extended hours are defined as work added onto the normal working hours (09:00-17:00 Monday to Friday), but not necessarily starting in working hours, for example CT dispensing required on a Tuesday 17:00-18:30. Whereas out-of-hours work is defined as weekend work or late evenings not following on from normal working hours, for example CT dispensing on a Tuesday 20:00-21:30 or Saturday morning |
| NIHR_DEPT_031 | Radiology CRA-requested dedicated Imaging staff time to support monitoring visits. Provision of basic access, hospitality, documentation provision and query response (per hour) to be paid quarterly in arrears | Radiology Departments | In Flight | £81 | |
| NIHR_DEPT_032 | Rqadiology revision of relevant SOPs or Imaging documentation as a result of a substantial protocol amendment (per hour) to be paid quarterly in arrears | Radiology Departments | In Flight | £81 | |
| NIHR_DEPT_033 | Radiotherapy Setup | Radiotherapy Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_034 | Specialist Medicine Setup | Specialist Medicine Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_035 | Pharmacy A: Dispensary based dispensing only with no aseptic dispensing | Pharmacy Departments | Setup | £1,772 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 21.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_036 | Pharmacy B: Aseptic dispensing only | Pharmacy Departments | Setup | £2,044 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 21.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_037 | Pharmacy C: Dispensary and aseptic dispensing | Pharmacy Departments | Setup | £2,453 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 30 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_038 | Pharmacy D: Cell based Gene Therapy setup | Pharmacy Departments | Setup | £31,640 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 385 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_039 | Pharmacy Set-up/close down for each additional site within the same NHS Trust (charged per site) | Pharmacy Departments | Setup | £209 | The base calculated figure is based upon 2.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_040 | Pharmacy IMP Management Fee per year per site (Annualised charge - pro rata as needed) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £601 | The IMP Management Fee is applicable to all studies requiring IMP management by an NHS Pharmacy. Full costs are chargeable unless Sponsor/CRO provide evidence and/ or information for specific Pharmacy requirements resulting in a suitable negotiated fee. Charged as an annual fee, which can be calculated pro rata as required, for the duration of the trial unless otherwise agreed and documented in the trial agreement. Stock checks are deemed part of routine standard practice, however any additional requirements (e.g. reporting or Company requested stock checks) may be charged as additional fees. Charged from month of site initiation visit to month of site close out visit. The following activities are included in as IMP Management Activities: Temperature management activities other than providing evidence of temperature to sponsors Temperature excursion management Expiry date checking |
| NIHR_DEPT_041 | Pharmacy Prescription Charge to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site. Standard NHS Prescription charge to be added directly to contract if applicable |
| NIHR_DEPT_042 | Pharmacy Storage space per month to cover charge incurred by Pharmacy for additional space within each NHS Trust regardless of temperature requirements (per site charge as required) | Pharmacy Departments | In Flight | £55 | |
| NIHR_DEPT_043 | Pharmacy Receiving Shipment to be paid quarterly in arrears | Pharmacy Departments | In Flight | £55 | |
| NIHR_DEPT_044 | Pharmacy Waste disposal management inc paperwork, logs etc to be paid quarterly in arrears | Pharmacy Departments | In Flight | £45 | |
| NIHR_DEPT_045 | Pharmacy Packaging returns for return to sponsor to be paid quarterly in arrears | Pharmacy Departments | In Flight | £33 | |
| NIHR_DEPT_046 | Pharmacy Specialist storage requirements for advanced therapy/radiopharmaceuticals (e.g. dry shipper containing liquid nitrogen or minus 80C freezers) (per site charge as required) to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_047 | Pharmacy Specialist transportation requirements for advanced therapy/radiopharmaceuticals (e.g. dry shipper, dry ice, spillage kits, courier costs) (per site charge as required) to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_048 | Pharmacy Waste disposal storage pending collection or disposal of all medicines originally supplied by Sponsor per month or part thereof (per site charge as required). Chargeable only if not collected within 1 month of the first request to collect | Pharmacy Departments | In Flight | £27 | Patient returns storage, usually not monitored. |
| NIHR_DEPT_049 | Pharmacy Storage or disposal of all unused/expired medicines originally supplied by Sponsor. Chargeable if not collected within 1 month of the first request and to be paid per month quarterly in arrears. | Pharmacy Departments | In Flight | £55 | Unused/expired stock at the end of the study that never left pharmacy and has to be maintained in quarantine (temperature monitored) until the Sponsor collects/reconciles. |
| NIHR_DEPT_050 | Pharmacy Re-labelling and releasing of IMP batch (Usual staff hourly rate) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £81 | |
| NIHR_DEPT_051 | Pharmacy Extending working hours (Usual staff hourly rate + 50%) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £121 | Extended hours are defined as work added onto the normal working hours (09:00-17:00 Monday to Friday), but not necessarily starting in working hours, for example CT dispensing required on a Tuesday 17:00-18:30. Whereas out-of-hours work is defined as weekend work or late evenings not following on from normal working hours, for example CT dispensing on a Tuesday 20:00-21:30 or Saturday morning |
| NIHR_DEPT_052 | Pharmacy Out-of-hours working (Usual staff hourly rate + 100%) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £161 | Extended hours are defined as work added onto the normal working hours (09:00-17:00 Monday to Friday), but not necessarily starting in working hours, for example CT dispensing required on a Tuesday 17:00-18:30. Whereas out-of-hours work is defined as weekend work or late evenings not following on from normal working hours, for example CT dispensing on a Tuesday 20:00-21:30 or Saturday morning |
| NIHR_DEPT_053 | Pharmacy Pharmacy staff time to support monitoring visits inc remote monitoring. Chargeable on an hourly rate to be paid quarterly in arrears | Pharmacy Departments | In Flight | £81 | |
| NIHR_DEPT_054 | Pharmacy IVRS/ study specific training as required by sponsor. Chargeable on an hourly rate. to be paid quarterly in arrears | Pharmacy Departments | In Flight | £81 | |
| NIHR_DEPT_055 | Pharmacy Individual training sessions for handling and preparation of study advanced therapy/radiopharmaceutical (usual staff hourly rate) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £81 | |
| NIHR_DEPT_056 | Pharmacy Time to assess whether revision of relevant SOPs or IMP documentation is required as a result of a protocol, Investigational Brochure or pharmacy manual amendment (Usual staff hourly rate) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £81 | |
| NIHR_DEPT_057 | Pharmacy Sponsor requested stock or temperature checks (Usual staff hourly rate) to be paid quarterly in arrears | Pharmacy Departments | In Flight | £81 | |
| NIHR_DEPT_058 | Pharmacy IMP release by Qualified Person (QP), if required (QP actual hourly rate) to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_059 | Pharmacy Study or IMP specific consumables for Pharmacy (total cost) to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_060 | Pharmacy Equipment purchase for specific IMP requirements in storage space or conditions (total cost) to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_061 | Device/ Clinical Equipment Courier/ posting costs for IMPs (third party costs as required e.g. per patient, sponsor returns) to be paid quarterly in arrears | Pharmacy Departments | In Flight | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_062 | Device/ Clinical Equipment A: Supply or device is to be checked and reviewed by only the research team | Device/ Clinical Equipment | Setup | £76 | |
| NIHR_DEPT_063 | Device/ Clinical Equipment B: Consultation with only one Trust service support department or other provider (e.g., Medical Physics, Electrical Engineering, Lab Based Medicines or Other specialists departments or providers) | Device/ Clinical Equipment | Setup | £149 | |
| NIHR_DEPT_064 | Device/ Clinical Equipment C: Consultation with more than one department | Device/ Clinical Equipment | Setup | £223 | |
| NIHR_DEPT_065 | Device/ Clinical Equipment D: No consultation with research staff required | Device/ Clinical Equipment | Setup | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_066 | Device/ Clinical Equipment Device Management Fee per month per site to be paid quarterly in arrears | Device/ Clinical Equipment | In Flight | £81 | The Trial Maintenance Activities fee covers: Routine stock checks Stock and accessory ordering and invoicing Device maintenance Contenting for device failure, malfunction, removal and returns Equipment sterilisation Regular checking and testing of equipment Maintaining the accountability log Tracking of device Communications with the company |
| NIHR_DEPT_067 | Pathology Setup | Pathology Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_068 | Radiology Setup | Radiology Departments | Setup | £274 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set up supply systems Train all relevant departmental staff, as required Close down. The base calculated figure is based upon 7.5 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_069 | Pharmacy Specialist profession oversight fee for advanced therapies or radiopharmaceuticals. Annulised charge pro rata as needed | Pharmacy Departments | Setup | TBC | To be discussed directly between Sponsor and local site |
| NIHR_DEPT_072 | Pharmacy E: Virus based Gene Therapy setup | Pharmacy Departments | Setup | £8,437 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 102 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_073 | Pharmacy F: Somatic Cell Therapy setup | Pharmacy Departments | Setup | £21,093 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 256 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_074 | Pharmacy G: Tissue engineered product setup | Pharmacy Departments | Setup | £21,093 | Review protocol Feasibility assessment Communication with the sponsor Participation in mandatory local review and approval processes Attendance at meetings & liaison with PI, Research Nurse, CRA Write bespoke SOPs, associated documents and worksheets Set up dispensing & stock control software systems and documentation Set-up electronic prescribing and Pharmacy systems, where applicable Set up supply systems Train all relevant Pharmacy staff, as required Review contract including pharmacy costing Close down. The base calculated figure is based upon 256 hours setup time required by Managerial and administrative grade staff. |
| NIHR_DEPT_075 | Full Day non-triggered Sponsor/ CRO audit | Study Team | In Flight | £1,028 | Communication with the sponsor Participation in mandatory processes as dictated by audit requirements Attendance at meetings & liaison with PI, Research Nurse, CRA Presentation of bespoke SOPs, associated documents and worksheets Presentation of dispensing & stock control software systems and documentation Presentation of training logs for all relevant departmental staff, as required All other activity as required by statutory audit requirements The base calculated figure is based upon 8 hours setup time required by Medical and grade staff. |
| NIHR_DEPT_076 | Medical Staff Out-of-hours working (Usual staff hourly rate + 100%) to be paid quarterly in arrears | Study Team | In Flight | £194 | Extended hours are defined as work added onto the normal working hours (09:00-17:00 Monday to Friday), but not necessarily starting in working hours, for example CT dispensing required on a Tuesday 17:00-18:30. Whereas out-of-hours work is defined as weekend work or late evenings not following on from normal working hours, for example signatures or prescriptions on a Tuesday 20:00-21:30 or Saturday morning |
no reviews yet
Please Login to review.
